Identification
NameRisperidone
Accession NumberDB00734  (APRD00187)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors. It is used primarily in the management of schizophrenia, inappropriate behavior in severe dementia and manic episodes associated with bipolar I disorder. Risperidone is effective for treating the positive and negative symptoms of schizophrenia owing to its affinity for its “loose” binding affinity for dopamine D2 receptors and additional 5-HT antagonism compared to first generation antipsychotics, which are strong, non-specific dopamine D2 receptor antagonists.

Structure
Thumb
Synonyms
risperdone
Risperidona
Risperidonum
Risperin
Rispolept
Rispolin
Sequinan
External IDs N05AX08 / R-64,766 / R-64766 / RCN-3028 / RCN3028
Product Ingredients Not Available
Product Images
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act RisperidoneTablet0.5 mgOralActavis Pharma Company2006-07-05Not applicableCanada
Act RisperidoneTablet3 mgOralActavis Pharma Company2006-07-05Not applicableCanada
Act RisperidoneTablet0.25 mgOralActavis Pharma Company2006-07-05Not applicableCanada
Act RisperidoneTablet1 mgOralActavis Pharma Company2006-07-05Not applicableCanada
Act RisperidoneTablet4 mgOralActavis Pharma Company2006-07-05Not applicableCanada
Act RisperidoneTablet2 mgOralActavis Pharma Company2006-07-05Not applicableCanada
Ag-risperidoneTablet2.0 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-risperidoneTablet0.50 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-risperidoneTablet3.0 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-risperidoneTablet1.0 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-risperidoneTablet4.0 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-risperidoneTablet0.25 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ava-risperidoneTablet1.0 mgOralAvanstra Inc2011-08-182014-08-21Canada
Ava-risperidoneTablet4.0 mgOralAvanstra Inc2011-08-182014-08-21Canada
Ava-risperidoneTablet0.5 mgOralAvanstra Inc2011-08-182014-08-21Canada
Ava-risperidoneSolution1 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-risperidoneTablet2.0 mgOralAvanstra Inc2011-08-182014-08-21Canada
Ava-risperidoneTablet3.0 mgOralAvanstra Inc2011-08-182014-08-21Canada
Ava-risperidoneTablet0.25 mgOralAvanstra Inc2011-08-182014-08-21Canada
Dom-risperidoneTablet3.0 mgOralDominion Pharmacal2006-08-08Not applicableCanada
Dom-risperidoneTablet1.0 mgOralDominion Pharmacal2006-08-08Not applicableCanada
Dom-risperidoneTablet4.0 mgOralDominion Pharmacal2006-08-08Not applicableCanada
Dom-risperidoneTablet0.25 mgOralDominion Pharmacal2006-08-08Not applicableCanada
Dom-risperidoneTablet2.0 mgOralDominion Pharmacal2006-08-08Not applicableCanada
Dom-risperidoneSolution1 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-risperidoneTablet0.5 mgOralDominion Pharmacal2006-08-08Not applicableCanada
Dom-risperidone ODTTablet, orally disintegrating1 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-risperidone ODTTablet, orally disintegrating2 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-risperidone ODTTablet, orally disintegrating0.5 mgOralDominion PharmacalNot applicableNot applicableCanada
Ipg-risperidoneTablet0.5 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-risperidoneTablet4 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-risperidoneTablet3 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-risperidoneTablet1 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-risperidoneTablet2 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-risperidoneTablet0.25 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-risperidoneTablet3.0 mgOralJamp Pharma Corporation2010-12-23Not applicableCanada
Jamp-risperidoneTablet1.0 mgOralJamp Pharma Corporation2010-12-23Not applicableCanada
Jamp-risperidoneTablet4.0 mgOralJamp Pharma Corporation2010-12-23Not applicableCanada
Jamp-risperidoneSolution1 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
Jamp-risperidoneTablet0.25 mgOralJamp Pharma Corporation2010-12-23Not applicableCanada
Jamp-risperidoneTablet2.0 mgOralJamp Pharma Corporation2010-12-23Not applicableCanada
Jamp-risperidoneTablet0.50 mgOralJamp Pharma Corporation2010-12-23Not applicableCanada
Mar-risperidoneTablet0.25 mgOralMarcan Pharmaceuticals Inc2013-04-17Not applicableCanada
Mar-risperidoneTablet2.0 mgOralMarcan Pharmaceuticals Inc2013-04-17Not applicableCanada
Mar-risperidoneTablet0.50 mgOralMarcan Pharmaceuticals Inc2013-04-17Not applicableCanada
Mar-risperidoneTablet3.0 mgOralMarcan Pharmaceuticals Inc2013-04-17Not applicableCanada
Mar-risperidoneTablet1.0 mgOralMarcan Pharmaceuticals Inc2013-04-17Not applicableCanada
Mar-risperidoneTablet4.0 mgOralMarcan Pharmaceuticals Inc2013-04-17Not applicableCanada
Mint-risperidonTablet0.25 mgOralMint Pharmaceuticals Inc2011-01-05Not applicableCanada
Mint-risperidonTablet2.0 mgOralMint Pharmaceuticals Inc2011-01-05Not applicableCanada
Mint-risperidonTablet0.50 mgOralMint Pharmaceuticals Inc2011-01-05Not applicableCanada
Mint-risperidonTablet3.0 mgOralMint Pharmaceuticals Inc2011-01-05Not applicableCanada
Mint-risperidonTablet1.0 mgOralMint Pharmaceuticals Inc2011-01-05Not applicableCanada
Mint-risperidonTablet4.0 mgOralMint Pharmaceuticals Inc2011-01-05Not applicableCanada
Mylan-risperidoneTablet4.0 mgOralMylan Pharmaceuticals2006-07-05Not applicableCanada
Mylan-risperidoneTablet0.25 mgOralMylan Pharmaceuticals2006-07-05Not applicableCanada
Mylan-risperidoneTablet2.0 mgOralMylan Pharmaceuticals2006-07-05Not applicableCanada
Mylan-risperidoneTablet0.50 mgOralMylan Pharmaceuticals2006-07-05Not applicableCanada
Mylan-risperidoneTablet3.0 mgOralMylan Pharmaceuticals2006-07-05Not applicableCanada
Mylan-risperidoneTablet1.0 mgOralMylan Pharmaceuticals2006-07-05Not applicableCanada
Mylan-risperidone ODTTablet, orally disintegrating2 mgOralMylan Pharmaceuticals2013-10-24Not applicableCanada
Mylan-risperidone ODTTablet, orally disintegrating0.5 mgOralMylan Pharmaceuticals2013-10-24Not applicableCanada
Mylan-risperidone ODTTablet, orally disintegrating3 mgOralMylan Pharmaceuticals2013-10-24Not applicableCanada
Mylan-risperidone ODTTablet, orally disintegrating1 mgOralMylan Pharmaceuticals2013-10-24Not applicableCanada
Mylan-risperidone ODTTablet, orally disintegrating4 mgOralMylan Pharmaceuticals2013-10-24Not applicableCanada
Nu-risperidoneTablet2 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-risperidoneTablet0.5 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-risperidoneTablet3 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-risperidoneTablet1 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-risperidoneTablet4 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-risperidoneTablet0.25 mgOralNu Pharm IncNot applicableNot applicableCanada
PHL-risperidoneTablet2.0 mgOralPharmel Inc2006-08-09Not applicableCanada
PHL-risperidoneTablet0.5 mgOralPharmel Inc2006-08-09Not applicableCanada
PHL-risperidoneTablet3.0 mgOralPharmel Inc2006-08-09Not applicableCanada
PHL-risperidoneTablet1.0 mgOralPharmel Inc2006-08-09Not applicableCanada
PHL-risperidoneTablet4.0 mgOralPharmel Inc2006-08-09Not applicableCanada
PHL-risperidoneTablet0.25 mgOralPharmel Inc2006-08-09Not applicableCanada
PHL-risperidone ODTTablet, orally disintegrating2 mgOralPharmel IncNot applicableNot applicableCanada
PHL-risperidone ODTTablet, orally disintegrating0.5 mgOralPharmel IncNot applicableNot applicableCanada
PHL-risperidone ODTTablet, orally disintegrating1 mgOralPharmel IncNot applicableNot applicableCanada
PMS-risperidoneTablet3.0 mgOralPharmascience Inc2006-07-05Not applicableCanada
PMS-risperidoneTablet0.25 mgOralPharmascience Inc2006-07-05Not applicableCanada
PMS-risperidoneTablet2.0 mgOralPharmascience Inc2006-07-05Not applicableCanada
PMS-risperidoneTablet0.5 mgOralPharmascience Inc2006-07-05Not applicableCanada
PMS-risperidoneTablet4.0 mgOralPharmascience Inc2006-07-05Not applicableCanada
PMS-risperidoneTablet1.0 mgOralPharmascience Inc2006-07-05Not applicableCanada
PMS-risperidoneSolution1 mgOralPharmascience Inc2006-07-05Not applicableCanada
PMS-risperidone ODTTablet, orally disintegrating2 mgOralPharmascience Inc2007-03-13Not applicableCanada
PMS-risperidone ODTTablet, orally disintegrating4 mgOralPharmascience Inc2011-12-16Not applicableCanada
PMS-risperidone ODTTablet, orally disintegrating1 mgOralPharmascience Inc2007-03-13Not applicableCanada
PMS-risperidone ODTTablet, orally disintegrating0.5 mgOralPharmascience Inc2007-03-13Not applicableCanada
PMS-risperidone ODTTablet, orally disintegrating3 mgOralPharmascience Inc2011-12-16Not applicableCanada
Pro-risperidoneTablet3.0 mgOralPro Doc Limitee2008-07-09Not applicableCanada
Pro-risperidoneTablet1.0 mgOralPro Doc Limitee2008-07-09Not applicableCanada
Pro-risperidoneTablet4.0 mgOralPro Doc Limitee2008-07-09Not applicableCanada
Pro-risperidoneTablet0.25 mgOralPro Doc Limitee2008-07-09Not applicableCanada
Pro-risperidoneTablet2.0 mgOralPro Doc Limitee2008-07-09Not applicableCanada
Pro-risperidoneTablet0.5 mgOralPro Doc Limitee2008-07-09Not applicableCanada
Q-risperidoneTablet2 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-risperidoneTablet0.25 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-risperidoneTablet0.5 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-risperidoneTablet3 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-risperidoneTablet1 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-risperidoneTablet4 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Ran-risperidoneTablet1.0 mgOralRanbaxy Inc.2009-10-22Not applicableCanada
Ran-risperidoneTablet0.5 mgOralRanbaxy Inc.2009-10-22Not applicableCanada
Ran-risperidoneTablet4.0 mgOralRanbaxy Inc.2009-10-22Not applicableCanada
Ran-risperidoneTablet0.5 mgOralRanbaxy Inc.2006-06-302012-06-13Canada
Ran-risperidoneTablet3 mgOralRanbaxy Inc.2006-06-302012-06-13Canada
Ran-risperidoneTablet2.0 mgOralRanbaxy Inc.2009-10-22Not applicableCanada
Ran-risperidoneTablet1 mgOralRanbaxy Inc.2006-06-302012-06-13Canada
Ran-risperidoneTablet4 mgOralRanbaxy Inc.2006-06-302012-06-13Canada
Ran-risperidoneTablet0.25 mgOralRanbaxy Inc.2009-10-22Not applicableCanada
Ran-risperidoneTablet3.0 mgOralRanbaxy Inc.2009-10-22Not applicableCanada
Ran-risperidoneTablet0.25 mgOralRanbaxy Inc.2006-06-302012-06-13Canada
Ran-risperidoneTablet2 mgOralRanbaxy Inc.2006-06-302012-06-13Canada
Ratio-risperidoneTablet2.0 mgOralRatiopharm Inc Division Of Teva Canada Limited2006-07-052015-10-26Canada
Ratio-risperidoneTablet0.5 mgOralRatiopharm Inc Division Of Teva Canada Limited2006-07-052015-10-26Canada
Ratio-risperidoneTablet3.0 mgOralRatiopharm Inc Division Of Teva Canada Limited2006-07-052015-10-26Canada
Ratio-risperidoneTablet1.0 mgOralRatiopharm Inc Division Of Teva Canada Limited2006-07-052015-10-26Canada
Ratio-risperidoneTablet4.0 mgOralRatiopharm Inc Division Of Teva Canada Limited2006-07-052015-10-26Canada
Ratio-risperidoneTablet0.25 mgOralRatiopharm Inc Division Of Teva Canada Limited2006-07-052015-10-26Canada
RisperdalTablet.5 mg/1OralCardinal Health1993-12-29Not applicableUs
RisperdalTablet1 mg/1OralPd Rx Pharmaceuticals, Inc.1993-12-29Not applicableUs
RisperdalSolution1 mg/mLOralJanssen Pharmaceuticals1996-06-10Not applicableUs
RisperdalTablet4 mg/1OralRemedy Repack2017-01-19Not applicableUs
RisperdalTablet1 mg/1OralRebel Distributors1993-12-29Not applicableUs50458 0300 06 nlmimage10 35241a80
RisperdalTablet5 mgOralJanssen Pharmaceuticals1999-05-282009-08-05Canada
RisperdalTablet3 mgOralJanssen Pharmaceuticals1993-12-31Not applicableCanada
RisperdalTablet4 mg/1OralPd Rx Pharmaceuticals, Inc.1993-12-29Not applicableUs
RisperdalTablet1 mg/1OralRemedy Repack2016-05-18Not applicableUs
RisperdalTablet.25 mg/1OralJanssen Pharmaceuticals1993-12-29Not applicableUs
RisperdalTablet4 mg/1OralJanssen Pharmaceuticals1993-12-29Not applicableUs
RisperdalTablet0.25 mgOralJanssen Pharmaceuticals1999-09-17Not applicableCanada
RisperdalTablet2 mg/1OralCardinal Health1993-12-29Not applicableUs
RisperdalTablet2 mgOralJanssen Pharmaceuticals1993-12-31Not applicableCanada
RisperdalTablet.5 mg/1OralPd Rx Pharmaceuticals, Inc.1993-12-29Not applicableUs
RisperdalTablet3 mg/1OralRebel Distributors1993-12-29Not applicableUs
RisperdalTablet4 mgOralJanssen Pharmaceuticals1993-12-31Not applicableCanada
RisperdalTablet.5 mg/1OralRemedy Repack2013-05-072016-04-05Us
RisperdalTablet3 mg/1OralJanssen Pharmaceuticals1993-12-29Not applicableUs
RisperdalTablet.5 mg/1OralJanssen Pharmaceuticals1993-12-29Not applicableUs
RisperdalTablet0.5 mgOralJanssen Pharmaceuticals1999-09-17Not applicableCanada
RisperdalTablet3 mg/1OralCardinal Health1993-12-29Not applicableUs
RisperdalTablet2 mg/1OralPd Rx Pharmaceuticals, Inc.1993-12-29Not applicableUs
RisperdalTablet.5 mg/1OralRemedy Repack2013-05-062016-04-05Us
RisperdalTablet2 mg/1OralRemedy Repack2016-05-18Not applicableUs
RisperdalTablet2 mg/1OralJanssen Pharmaceuticals1993-12-29Not applicableUs
RisperdalTablet1 mgOralJanssen Pharmaceuticals1993-12-31Not applicableCanada
RisperdalTablet3 mg/1OralRemedy Repack2016-05-22Not applicableUs
RisperdalTablet1 mg/1OralCardinal Health1993-12-29Not applicableUs
RisperdalTablet1 mg/1OralJanssen Pharmaceuticals1993-12-29Not applicableUs
Risperdal ConstaKitJanssen Pharmaceuticals2003-10-29Not applicableUs
Risperdal ConstaInjection, powder, for suspension, extended release; Kit37.5 mgIntramuscularJanssen Pharmaceuticals2004-09-08Not applicableCanada
Risperdal ConstaKitJanssen Pharmaceuticals2003-10-29Not applicableUs
Risperdal ConstaKitJanssen Pharmaceuticals2003-10-29Not applicableUs
Risperdal ConstaInjection, powder, for suspension, extended release; Kit12.5 mgIntramuscularJanssen Pharmaceuticals2007-10-24Not applicableCanada
Risperdal ConstaInjection, powder, for suspension, extended release; Kit50 mgIntramuscularJanssen Pharmaceuticals2004-09-08Not applicableCanada
Risperdal ConstaInjection, powder, for suspension, extended release; Kit25 mgIntramuscularJanssen Pharmaceuticals2004-09-08Not applicableCanada
Risperdal ConstaKitJanssen Pharmaceuticals2003-10-29Not applicableUs
Risperdal M-tabTablet, orally disintegrating.5 mg/1OralJanssen Pharmaceuticals2003-04-02Not applicableUs
Risperdal M-tabTablet, orally disintegrating2 mg/1OralJanssen Pharmaceuticals2003-04-02Not applicableUs
Risperdal M-tabTablet, orally disintegrating0.5 mgOralJanssen Pharmaceuticals2003-07-272017-05-26Canada
Risperdal M-tabTablet, orally disintegrating3 mgOralJanssen Pharmaceuticals2005-06-202016-11-29Canada
Risperdal M-tabTablet, orally disintegrating1 mg/1OralJanssen Pharmaceuticals2003-04-02Not applicableUs
Risperdal M-tabTablet, orally disintegrating1 mgOralJanssen Pharmaceuticals2003-07-272017-02-02Canada
Risperdal M-tabTablet, orally disintegrating4 mg/1OralJanssen Pharmaceuticals2003-04-02Not applicableUs
Risperdal M-tabTablet, orally disintegrating4 mgOralJanssen Pharmaceuticals2005-06-202016-09-28Canada
Risperdal M-tabTablet, orally disintegrating2 mgOralJanssen Pharmaceuticals2003-07-272017-01-04Canada
Risperdal M-tabTablet, orally disintegrating3 mg/1OralJanssen Pharmaceuticals2003-04-02Not applicableUs
Risperdal Oral SolutionSolution1 mgOralJanssen Pharmaceuticals1998-03-04Not applicableCanada
RisperidoneTablet4.0 mgOralMeliapharm Inc2009-02-262014-06-25Canada
RisperidoneTablet2 mg/1OralJanssen Pharmaceuticals1993-12-29Not applicableUs50458 0593 60 nlmimage10 c633e34f
RisperidoneTablet0.5 mgOralSanis Health Inc2010-10-21Not applicableCanada
RisperidoneTablet2 mg/1OralCardinal Health1993-12-29Not applicableUs
RisperidoneTablet0.5 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
RisperidoneTablet0.25 mgOralSanis Health Inc2010-10-21Not applicableCanada
RisperidoneTablet.5 mg/1OralRemedy Repack2013-05-062016-10-13Us
RisperidoneTablet0.25 mgOralMeliapharm Inc2009-02-262014-06-25Canada
RisperidoneTablet3.0 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
RisperidoneTablet1 mg/1OralCardinal Health1993-12-29Not applicableUs
RisperidoneSolution1 mg/mLOralJanssen Pharmaceuticals1996-06-10Not applicableUs
RisperidoneTablet0.25 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
RisperidoneTablet3 mgOralSanis Health Inc2010-10-21Not applicableCanada
RisperidoneTablet1 mg/1OralJanssen Pharmaceuticals1993-12-29Not applicableUs50458 0592 60 nlmimage10 f4347a63
RisperidoneTablet2.0 mgOralMeliapharm Inc2009-02-262014-06-25Canada
RisperidoneTablet1.0 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
RisperidoneTablet.25 mg/1OralCardinal Health1993-12-29Not applicableUs
RisperidoneTablet3 mg/1OralJanssen Pharmaceuticals1993-12-29Not applicableUs
RisperidoneTablet1 mgOralSanis Health Inc2010-10-21Not applicableCanada
RisperidoneTablet.25 mg/1OralJanssen Pharmaceuticals1993-12-29Not applicableUs
RisperidoneTablet0.5 mgOralMeliapharm Inc2009-02-262014-06-25Canada
RisperidoneTablet4.0 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
RisperidoneTablet1 mg/1OralA S Medication Solutions1993-12-292017-06-20Us
RisperidoneTablet4 mgOralSanis Health Inc2010-10-21Not applicableCanada
RisperidoneTablet3.0 mgOralMeliapharm Inc2009-02-262014-06-25Canada
RisperidoneTablet2.0 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
RisperidoneTablet.5 mg/1OralCardinal Health1993-12-29Not applicableUs
RisperidoneTablet4 mg/1OralJanssen Pharmaceuticals1993-12-29Not applicableUs
RisperidoneTablet2 mgOralSanis Health Inc2010-10-21Not applicableCanada
RisperidoneTablet.5 mg/1OralJanssen Pharmaceuticals1993-12-29Not applicableUs
RisperidoneTablet1.0 mgOralMeliapharm Inc2009-02-262014-06-25Canada
Risperidone - 0.25Tablet0.25 mgOralPro Doc Limitee2007-10-292008-07-25Canada
Risperidone - 0.5Tablet0.50 mgOralPro Doc Limitee2007-10-292008-07-25Canada
Risperidone - 1Tablet1.0 mgOralPro Doc Limitee2007-10-292008-07-25Canada
Risperidone - 2Tablet2.0 mgOralPro Doc Limitee2007-10-292008-07-25Canada
Risperidone - 3Tablet3.0 mgOralPro Doc Limitee2007-10-292008-07-25Canada
Risperidone - 4Tablet4.0 mgOralPro Doc Limitee2007-10-292008-07-25Canada
Risperidone M-TABTablet, orally disintegrating4 mg/1OralJanssen Pharmaceuticals2003-04-02Not applicableUs
Risperidone M-TABTablet, orally disintegrating2 mg/1OralJanssen Pharmaceuticals2003-04-02Not applicableUs
Risperidone M-TABTablet, orally disintegrating.5 mg/1OralJanssen Pharmaceuticals2003-04-02Not applicableUs
Risperidone M-TABTablet, orally disintegrating3 mg/1OralJanssen Pharmaceuticals2003-04-02Not applicableUs
Risperidone M-TABTablet, orally disintegrating1 mg/1OralJanssen Pharmaceuticals2003-04-02Not applicableUs
Risperidone TabletsTablet0.5 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Risperidone TabletsTablet3.0 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Risperidone TabletsTablet0.25 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Risperidone TabletsTablet1.0 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Risperidone TabletsTablet4.0 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Risperidone TabletsTablet2.0 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Riva-risperidoneTablet3 mgOralLaboratoire Riva Inc2006-07-31Not applicableCanada
Riva-risperidoneTablet1 mgOralLaboratoire Riva Inc2006-07-31Not applicableCanada
Riva-risperidoneTablet4 mgOralLaboratoire Riva Inc2006-07-31Not applicableCanada
Riva-risperidoneTablet0.25 mgOralLaboratoire Riva Inc2006-07-31Not applicableCanada
Riva-risperidoneTablet2 mgOralLaboratoire Riva Inc2006-07-31Not applicableCanada
Riva-risperidoneTablet0.5 mgOralLaboratoire Riva Inc2006-07-31Not applicableCanada
Sandoz RisperidoneTablet0.5 mgOralSandoz Canada Incorporated2006-07-052008-08-07Canada
Sandoz RisperidoneTablet2.0 mgOralSandoz Canada Incorporated2006-07-05Not applicableCanada
Sandoz RisperidoneTablet0.25 mgOralSandoz Canada Incorporated2007-03-082008-08-07Canada
Sandoz RisperidoneTablet0.5 mgOralSandoz Canada Incorporated2007-12-21Not applicableCanada
Sandoz RisperidoneTablet1.0 mgOralSandoz Canada Incorporated2006-07-05Not applicableCanada
Sandoz RisperidoneTablet0.25 mgOralSandoz Canada Incorporated2006-07-052008-08-07Canada
Sandoz RisperidoneTablet3.0 mgOralSandoz Canada Incorporated2006-07-05Not applicableCanada
Sandoz RisperidoneTablet0.25 mgOralSandoz Canada Incorporated2007-12-21Not applicableCanada
Sandoz RisperidoneTablet4.0 mgOralSandoz Canada Incorporated2006-07-05Not applicableCanada
Teva-risperidoneTablet1.0 mgOralTeva2006-07-05Not applicableCanada
Teva-risperidoneTablet0.5 mgOralTeva2006-07-05Not applicableCanada
Teva-risperidoneTablet4.0 mgOralTeva2006-07-05Not applicableCanada
Teva-risperidoneTablet0.25 mgOralTeva2006-07-05Not applicableCanada
Teva-risperidoneTablet2.0 mgOralTeva2006-07-05Not applicableCanada
Teva-risperidoneTablet3.0 mgOralTeva2006-07-05Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-risperidoneSolution1 mgOralApotex Corporation2006-07-05Not applicableCanada
Apo-risperidoneTablet1.0 mgOralApotex Corporation2006-07-05Not applicableCanada
Apo-risperidoneTablet4.0 mgOralApotex Corporation2006-07-05Not applicableCanada
Apo-risperidoneTablet0.25 mgOralApotex Corporation2006-07-05Not applicableCanada
Apo-risperidoneTablet2.0 mgOralApotex Corporation2006-07-05Not applicableCanada
Apo-risperidoneTablet0.50 mgOralApotex Corporation2006-07-05Not applicableCanada
Apo-risperidoneTablet3.0 mgOralApotex Corporation2006-07-05Not applicableCanada
RisperidoneTablet, film coated3 mg/1OralCitron Pharma LLC2008-10-08Not applicableUs
RisperidoneTablet, coated4 mg/1OralRatiopharm Inc2010-06-08Not applicableUs
RisperidoneTablet2 mg/1OralMsm Repackaging2015-09-09Not applicableUs
RisperidoneTablet, film coated4 mg/1OralMylan Institutional2008-10-06Not applicableUs
RisperidoneTablet, film coated3 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-072017-03-15Us
RisperidoneTablet, film coated.25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2008-09-17Not applicableUs
RisperidoneTablet, film coated.25 mg/1OralProficient Rx LP2008-12-29Not applicableUs00603 5683 20 nlmimage10 090e84d4
RisperidoneTablet, orally disintegrating4 mg/1OralSandoz2009-12-22Not applicableUs
RisperidoneSolution1 mg/mLOralDr Reddy's Laboratories2009-07-29Not applicableUs
RisperidoneTablet.5 mg/1OralAjanta Pharma Limited2015-09-09Not applicableUs27241 0003 50 nlmimage10 40432039
RisperidoneTablet, film coated1 mg/1Oralbryant ranch prepack2008-12-29Not applicableUs
RisperidoneTablet, orally disintegrating.5 mg/1OralJubilant Cadista Pharmaceuticals Inc.2010-12-01Not applicableUs
RisperidoneTablet, film coated.5 mg/1OralCardinal Health2010-11-122016-04-05Us
RisperidoneTablet, orally disintegrating3 mg/1OralPar Pharmaceutical2009-06-01Not applicableUs
RisperidoneTablet1 mg/1OralBreckenridge Pharmaceutical, Inc.2012-04-25Not applicableUs
RisperidoneTablet, film coated4 mg/1OralWockhardt2008-10-09Not applicableUs
RisperidoneTablet, film coated4 mg/1OralAurobindo Pharma2008-10-08Not applicableUs
RisperidoneTablet3 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2014-03-10Not applicableUs
RisperidoneTablet3 mg/1OralRemedy Repack2015-03-03Not applicableUs
RisperidoneTablet, film coated4 mg/1OralGen Source Rx2009-10-252016-03-29Us
RisperidoneTablet, film coated2 mg/1OralCadila Pharnmaceuticals2008-11-13Not applicableUs
RisperidoneTablet, film coated.25 mg/1OralCitron Pharma LLC2008-10-08Not applicableUs
RisperidoneTablet, coated.5 mg/1OralRatiopharm Inc2010-06-08Not applicableUs
RisperidoneTablet, film coated2 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
RisperidoneTablet2 mg/1OralContract Pharmacy Services Pa2010-08-25Not applicableUs
RisperidoneTablet, film coated1 mg/1OralDoh Central Pharmacy2009-07-01Not applicableUs
RisperidoneTablet, orally disintegrating4 mg/1OralSun Pharmaceutical Industries Limited2013-04-132017-01-14Us
RisperidoneTablet2 mg/1OralSolco healthcare U.S., LLC2015-06-01Not applicableUs
RisperidoneTablet, film coated2 mg/1OralCobalt Laboratories2008-12-052017-02-15Us
RisperidoneTablet, film coated4 mg/1OralMylan Pharmaceuticals2008-09-15Not applicableUs
RisperidoneTablet, orally disintegrating.5 mg/1OralRanbaxy Inc.2010-08-06Not applicableUs
RisperidoneTablet.5 mg/1OralApotex Corporation2008-09-22Not applicableUs
RisperidoneTablet, orally disintegrating.25 mg/1OralPar Pharmaceutical2009-06-01Not applicableUs
RisperidoneTablet, film coated.5 mg/1OralWockhardt2008-10-09Not applicableUs
RisperidoneTablet3 mg/1OralTorrent Pharmaceuticals Limited2009-01-01Not applicableUs
RisperidoneTablet, film coated.5 mg/1OralGen Source Rx2009-10-252016-03-29Us
RisperidoneTablet, orally disintegrating2 mg/1OralCadila Pharnmaceuticals2010-06-29Not applicableUs
RisperidoneTablet2 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
RisperidoneTablet, film coated4 mg/1OralContract Pharmacy Services Pa2010-12-06Not applicableUs00093 7243 06 nlmimage10 7b293dd9
RisperidoneTablet.5 mg/1OralRemedy Repack2011-04-112016-10-13Us
RisperidoneTablet2 mg/1OralMajor2013-11-30Not applicableUs
RisperidoneTablet2 mg/1OralPhysicians Total Care, Inc.2011-04-08Not applicableUs
RisperidoneTablet, film coated4 mg/1OralAmerincan Health Packaging2008-12-02Not applicableUs68382 0117 14 nlmimage10 9b3ecde6
RisperidoneTablet, orally disintegrating1 mg/1OralMylan Institutional2011-06-10Not applicableUs00378 6044 28 nlmimage10 35419afc
RisperidoneTablet, film coated.25 mg/1OralQualitest2008-12-292016-07-31Us
RisperidoneTablet2 mg/1OralRebel Distributors2009-07-01Not applicableUs
RisperidoneTablet, film coated1 mg/1OralMc Kesson Contract Packaging2011-09-22Not applicableUs
RisperidoneTablet, orally disintegrating1 mg/1OralMylan Pharmaceuticals2011-05-11Not applicableUs
RisperidoneTablet, film coated2 mg/1OralDr Reddy's Laboratories2009-10-24Not applicableUs
RisperidoneTablet, film coated3 mg/1OralCardinal Health2010-11-122016-04-05Us
RisperidoneTablet, film coated1 mg/1OralRemedy Repack2010-01-122017-04-27Us
RisperidoneTablet, film coated3 mg/1OralCardinal Health2008-10-242016-10-13Us
RisperidoneTablet, orally disintegrating4 mg/1OralJubilant Cadista Pharmaceuticals Inc.2010-12-01Not applicableUs
RisperidoneTablet, film coated2 mg/1OralWockhardt2008-10-09Not applicableUs
RisperidoneTablet, film coated1 mg/1OralZydus Pharmaceuticals Usa, Inc.2008-11-13Not applicableUs
RisperidoneTablet3 mg/1OralClinical Solutions Wholsesale2009-01-01Not applicableUs
RisperidoneTablet, film coated1 mg/1OralAv Pak2014-08-27Not applicableUs
RisperidoneTablet, film coated4 mg/1OralAurolife Pharma, LLC2009-10-25Not applicableUs
RisperidoneTablet.25 mg/1OralCardinal Health2013-11-30Not applicableUs
RisperidoneTablet, film coated3 mg/1OralGen Source Rx2009-10-252016-03-29Us
RisperidoneTablet, film coated1 mg/1OralCadila Pharnmaceuticals2008-11-13Not applicableUs
RisperidoneTablet, film coated2 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
RisperidoneTablet1 mg/1OralContract Pharmacy Services Pa2010-08-25Not applicableUs68382 0114 05 nlmimage10 c13f609b
RisperidoneTablet1 mg/1OralRemedy Repack2013-04-302016-10-13Us
RisperidoneTablet, film coated.25 mg/1OralAurolife Pharma, LLC2009-10-25Not applicableUs
RisperidoneTablet, film coated1 mg/1OralDr Reddy's Laboratories2009-10-24Not applicableUs
RisperidoneTablet, film coated4 mg/1OralMc Kesson Contract Packaging2013-05-13Not applicableUs
RisperidoneTablet, film coated.25 mg/1OralMylan Institutional2008-10-06Not applicableUs
RisperidoneTablet, film coated2 mg/1OralQualitest2008-12-292016-09-30Us00603 5686 28 nlmimage10 060e8324
RisperidoneTablet1 mg/1OralAidarex Pharmaceuticals LLC2009-01-01Not applicableUs
RisperidoneTablet.25 mg/1OralApotex Corporation2008-09-22Not applicableUs
RisperidoneTablet, orally disintegrating4 mg/1OralMylan Pharmaceuticals2011-05-11Not applicableUs
RisperidoneTablet, orally disintegrating.5 mg/1OralDr Reddy's Laboratories2009-02-24Not applicableUs55111 0207 81 nlmimage10 d616eb47
RisperidoneTablet, orally disintegrating.5 mg/1OralMylan Pharmaceuticals2011-05-11Not applicableUs00378 6043 28 nlmimage10 3e419f4c
RisperidoneTablet, film coated.5 mg/1OralRemedy Repack2010-04-072017-08-02Us
RisperidoneTablet, film coated1 mg/1OralCardinal Health2008-12-02Not applicableUs
RisperidoneTablet, film coated.25 mg/1OralAurobindo Pharma2008-10-08Not applicableUs
RisperidoneSolution1 mg/mLOralWockhardt2009-10-14Not applicableUs
RisperidoneTablet, film coated4 mg/1OralZydus Pharmaceuticals Usa, Inc.2008-11-13Not applicableUs
RisperidoneTablet, film coated1 mg/1OralClinical Solutions Wholsesale2008-12-292017-06-22Us00603 5685 28 nlmimage10 cd04e687
RisperidoneTablet, film coated4 mg/1OralAv Pak2014-08-27Not applicableUs
RisperidoneTablet, film coated1 mg/1OralCobalt Laboratories2008-12-052017-02-15Us
RisperidoneSolution1 mg/mLOralAtlantic Biologicals Corps.2011-05-31Not applicableUs
RisperidoneTablet1 mg/1OralHikma Pharmaceutical2009-06-01Not applicableUs
RisperidoneTablet, film coated2 mg/1OralAphena Pharma Solutions Tennessee, Inc.2008-09-17Not applicableUs
RisperidoneTablet.5 mg/1OralBreckenridge Pharmaceutical, Inc.2012-04-25Not applicableUs
RisperidoneTablet1 mg/1OralMajor2013-11-30Not applicableUs
RisperidoneTablet, film coated.25 mg/1OralMylan Pharmaceuticals2008-09-15Not applicableUs
RisperidoneTablet1 mg/1OralProficient Rx LP2014-04-23Not applicableUs
RisperidoneTablet, film coated2 mg/1OralRemedy Repack2009-12-14Not applicableUs
RisperidoneTablet, film coated2 mg/1OralCardinal Health2008-10-242016-10-13Us
RisperidoneTablet4 mg/1OralAjanta Pharma Limited2015-09-09Not applicableUs
RisperidoneTablet, film coated3 mg/1Oralbryant ranch prepack2008-12-29Not applicableUs00603 5689 20 nlmimage10 fd0e7ed3
RisperidoneTablet, orally disintegrating3 mg/1OralJubilant Cadista Pharmaceuticals Inc.2010-12-01Not applicableUs
RisperidoneTablet, film coated1 mg/1OralWockhardt2008-10-09Not applicableUs
RisperidoneTablet, film coated2 mg/1OralNu Care Pharmaceuticals,inc.2008-11-13Not applicableUs
RisperidoneTablet4 mg/1OralBreckenridge Pharmaceutical, Inc.2012-04-25Not applicableUs
RisperidoneTablet, film coated1 mg/1OralTYA Pharmaceuticals2008-11-13Not applicableUs
RisperidoneTablet, film coated.5 mg/1OralZydus Pharmaceuticals Usa, Inc.2008-11-13Not applicableUs
RisperidoneTablet2 mg/1OralClinical Solutions Wholsesale2009-01-01Not applicableUs
RisperidoneTablet.25 mg/1OralRemedy Repack2015-04-14Not applicableUs27241 0002 50 nlmimage10 76433b39
RisperidoneTablet, film coated2 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs00093 7241 06 nlmimage10 8b2945ba
RisperidoneTablet, film coated.25 mg/1OralContract Pharmacy Services Pa2010-12-06Not applicableUs00093 0221 06 nlmimage10 9f294fda
RisperidoneTablet, film coated2 mg/1OralCitron Pharma LLC2008-10-08Not applicableUs
RisperidoneTablet, coated3 mg/1OralRatiopharm Inc2010-06-08Not applicableUs
RisperidoneTablet, film coated3 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
RisperidoneTablet, film coated.25 mg/1OralAmerincan Health Packaging2008-12-02Not applicableUs
RisperidoneTablet1 mg/1OralUnit Dose Services2009-01-01Not applicableUs
RisperidoneTablet, orally disintegrating2 mg/1OralSun Pharmaceutical Industries Limited2013-04-132017-01-14Us
RisperidoneTablet3 mg/1OralRemedy Repack2010-11-082016-10-13Us
RisperidoneTablet2 mg/1OralStat Rx USA2009-01-01Not applicableUs
RisperidoneTablet.25 mg/1OralAjanta Pharma Limited2015-09-09Not applicableUs
RisperidoneTablet, film coated.25 mg/1Oralbryant ranch prepack2008-12-29Not applicableUs
RisperidoneTablet3 mg/1OralApotex Corporation2008-09-22Not applicableUs
RisperidoneTablet, orally disintegrating2 mg/1OralPar Pharmaceutical2009-06-01Not applicableUs49884 0401 91 nlmimage10 421ca105
RisperidoneTablet, film coated3 mg/1OralWockhardt2008-10-09Not applicableUs
RisperidoneTablet, film coated3 mg/1OralClinical Solutions Wholsesale2008-11-13Not applicableUs
RisperidoneTablet4 mg/1OralHikma Pharmaceutical2009-06-01Not applicableUs
RisperidoneTablet.5 mg/1OralSolco healthcare U.S., LLC2015-06-01Not applicableUs
RisperidoneTablet, film coated2 mg/1OralMylan Pharmaceuticals2008-09-15Not applicableUs
RisperidoneTablet, orally disintegrating3 mg/1OralRanbaxy Inc.2010-08-06Not applicableUs
RisperidoneSolution1 mg/mLOralAmneal Pharmaceuticals2011-05-31Not applicableUs
RisperidoneTablet, film coated2 mg/1OralMc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation2012-03-19Not applicableUs
RisperidoneTablet1 mg/1OralTorrent Pharmaceuticals Limited2009-01-01Not applicableUs
RisperidoneTablet, film coated1 mg/1OralRemedy Repack2013-05-082016-10-13Us
RisperidoneTablet, orally disintegrating.5 mg/1OralCadila Pharnmaceuticals2010-06-29Not applicableUs
RisperidoneTablet2 mg/1OralRemedy Repack2015-12-23Not applicableUs
RisperidoneTablet, film coated1 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
RisperidoneTablet, film coated2 mg/1OralContract Pharmacy Services Pa2010-12-06Not applicableUs
RisperidoneTablet.5 mg/1OralPhysicians Total Care, Inc.2009-10-28Not applicableUs
RisperidoneTablet, film coated2 mg/1OralAmerincan Health Packaging2008-12-02Not applicableUs68382 0115 05 nlmimage10 9d3d4eaa
RisperidoneTablet.5 mg/1OralRebel Distributors2009-07-01Not applicableUs
RisperidoneTablet, film coated1 mg/1OralCardinal Health2010-11-122016-04-05Us
RisperidoneTablet, film coated2 mg/1OralRemedy Repack2013-05-012016-10-13Us
RisperidoneTablet, film coated2 mg/1OralAurolife Pharma, LLC2009-10-25Not applicableUs
RisperidoneTablet, film coated2 mg/1OralMylan Institutional2008-10-06Not applicableUs
RisperidoneTablet, film coated4 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-072017-03-15Us
RisperidoneTablet, orally disintegrating2 mg/1OralSandoz2009-12-22Not applicableUs
RisperidoneTablet, orally disintegrating3 mg/1OralDr Reddy's Laboratories2009-11-30Not applicableUs
RisperidoneSolution1 mg/mLOralBreckenridge Pharmaceutical, Inc.2014-01-29Not applicableUs
RisperidoneTablet, film coated1 mg/1OralCardinal Health2008-11-132017-05-16Us
RisperidoneTablet, film coated2 mg/1OralAurobindo Pharma2008-10-08Not applicableUs
RisperidoneTablet1 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2014-03-10Not applicableUs
RisperidoneTablet, orally disintegrating2 mg/1OralZydus Pharmaceuticals Usa, Inc.2010-06-29Not applicableUs
RisperidoneTablet, film coated3 mg/1OralClinical Solutions Wholsesale2008-12-292017-06-22Us
RisperidoneSolution1 mg/mLOralApotex Corporation2009-07-292017-04-14Us
RisperidoneTablet, film coated3 mg/1OralWockhardt2008-10-09Not applicableUs
RisperidoneTablet, film coated2 mg/1OralZydus Pharmaceuticals Usa, Inc.2008-11-13Not applicableUs
RisperidoneTablet, film coated.25 mg/1OralClinical Solutions Wholsesale2008-12-292017-06-22Us
RisperidoneTablet, film coated2 mg/1OralAv Pak2014-08-27Not applicableUs
RisperidoneTablet, film coated.25 mg/1OralCobalt Laboratories2008-12-052017-02-15Us
RisperidoneTablet, film coated4 mg/1OralCitron Pharma LLC2008-10-08Not applicableUs
RisperidoneTablet.25 mg/1OralHikma Pharmaceutical2009-06-01Not applicableUs
RisperidoneTablet, film coated4 mg/1OralAphena Pharma Solutions Tennessee, Inc.2008-09-17Not applicableUs
RisperidoneSolution1 mg/mLOralTaro Pharmaceuticals U.S.A., Inc.2011-02-07Not applicableUs
RisperidoneTablet.25 mg/1OralMajor2013-11-30Not applicableUs
RisperidoneTablet, film coated.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2008-09-17Not applicableUs
RisperidoneTablet, film coated.5 mg/1OralProficient Rx LP2008-12-29Not applicableUs
RisperidoneSolution1 mg/mLOralHeritage2013-07-15Not applicableUs
RisperidoneTablet, film coated.5 mg/1OralCardinal Health2008-10-242016-10-13Us
RisperidoneTablet2 mg/1OralAjanta Pharma Limited2015-09-09Not applicableUs
RisperidoneTablet, film coated2 mg/1Oralbryant ranch prepack2008-12-29Not applicableUs
RisperidoneTablet, orally disintegrating1 mg/1OralJubilant Cadista Pharmaceuticals Inc.2010-12-01Not applicableUs
RisperidoneTablet, film coated.25 mg/1OralWockhardt2008-10-09Not applicableUs
RisperidoneTablet, orally disintegrating4 mg/1OralPar Pharmaceutical2009-06-01Not applicableUs49884 0403 91 nlmimage10 3e1c9f54
RisperidoneTablet2 mg/1OralBreckenridge Pharmaceutical, Inc.2012-04-25Not applicableUs
RisperidoneSolution1 mg/mLOralWockhardt2009-10-14Not applicableUs
RisperidoneSolution1 mg/mLOralAurobindo Pharma2009-09-152017-07-06Us
RisperidoneTablet4 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2014-03-10Not applicableUs
RisperidoneTablet.5 mg/1OralRemedy Repack2015-03-17Not applicableUs
RisperidoneTablet.5 mg/1OralH.J. Harkins Company2009-01-01Not applicableUs
RisperidoneTablet, film coated3 mg/1OralCadila Pharnmaceuticals2008-11-13Not applicableUs
RisperidoneTablet, film coated.5 mg/1OralCitron Pharma LLC2008-10-08Not applicableUs
RisperidoneTablet, coated1 mg/1OralRatiopharm Inc2010-06-08Not applicableUs
RisperidoneTablet, film coated4 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
RisperidoneTablet3 mg/1OralContract Pharmacy Services Pa2010-08-25Not applicableUs
RisperidoneTablet2 mg/1OralA S Medication Solutions2013-11-302017-06-20Us
RisperidoneTablet, orally disintegrating.5 mg/1OralSun Pharmaceutical Industries Limited2013-04-132017-01-14Us
RisperidoneTablet3 mg/1OralSolco healthcare U.S., LLC2015-06-01Not applicableUs
RisperidoneTablet, film coated3 mg/1OralCobalt Laboratories2008-12-052017-02-15Us
RisperidoneSolution1 mg/mLOralPar Pharmaceutical2010-12-032019-07-31Us
RisperidoneTablet, orally disintegrating1 mg/1OralRanbaxy Inc.2010-08-06Not applicableUs
RisperidoneTablet1 mg/1OralApotex Corporation2008-09-22Not applicableUs
RisperidoneTablet, orally disintegrating.5 mg/1OralPar Pharmaceutical2009-06-01Not applicableUs
RisperidoneTablet, film coated1 mg/1OralWockhardt2008-10-09Not applicableUs
RisperidoneTablet4 mg/1OralTorrent Pharmaceuticals Limited2009-01-01Not applicableUs13668 0040 60 nlmimage10 9433ca5e
RisperidoneTablet, film coated1 mg/1OralGen Source Rx2009-10-252016-03-29Us
RisperidoneTablet, film coated.25 mg/1OralCadila Pharnmaceuticals2008-11-13Not applicableUs
RisperidoneTablet3 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs13668 0039 60 nlmimage10 030e81d4
RisperidoneTablet.25 mg/1OralContract Pharmacy Services Pa2010-08-25Not applicableUs
RisperidoneTablet.25 mg/1OralRemedy Repack2013-04-242016-10-13Us
RisperidoneTablet3 mg/1OralMajor2013-11-30Not applicableUs
RisperidoneTablet, film coated.25 mg/1OralDr Reddy's Laboratories2009-10-24Not applicableUs
RisperidoneTablet, film coated.25 mg/1OralMc Kesson Contract Packaging2011-10-13Not applicableUs
RisperidoneTablet, orally disintegrating2 mg/1OralMylan Institutional2011-06-10Not applicableUs
RisperidoneTablet, film coated.5 mg/1OralQualitest2008-12-292016-07-31Us
RisperidoneTablet3 mg/1OralRebel Distributors2009-07-01Not applicableUs
RisperidoneTablet, film coated2 mg/1OralMc Kesson Contract Packaging2011-09-14Not applicableUs
RisperidoneTablet, orally disintegrating2 mg/1OralMylan Pharmaceuticals2011-05-11Not applicableUs
RisperidoneTablet, film coated3 mg/1OralDr Reddy's Laboratories2009-10-24Not applicableUs
RisperidoneSolution1 mg/mLOralWest Ward Pharmaceutical2009-07-29Not applicableUs
RisperidoneTablet, film coated3 mg/1OralRemedy Repack2010-01-13Not applicableUs
RisperidoneTablet, film coated4 mg/1OralCardinal Health2008-10-242016-10-13Us
RisperidoneSolution1 mg/mLOralAtlantic Biologicals Corps.2011-05-31Not applicableUs
RisperidoneTablet4 mg/1OralApotex Corporation2008-09-22Not applicableUs
RisperidoneTablet.25 mg/1OralRemedy Repack2011-03-282016-10-13Us
RisperidoneTablet, film coated.5 mg/1OralAurolife Pharma, LLC2009-10-25Not applicableUs
RisperidoneTablet, film coated.5 mg/1OralMylan Institutional2008-10-06Not applicableUs
RisperidoneTablet, film coated4 mg/1OralQualitest2008-12-292016-07-31Us
RisperidoneTablet, orally disintegrating.5 mg/1OralSandoz2009-12-22Not applicableUs00781 5310 06 nlmimage10 243f925c
RisperidoneTablet, orally disintegrating1 mg/1OralDr Reddy's Laboratories2009-10-06Not applicableUs
RisperidoneTablet, film coated.25 mg/1OralRemedy Repack2010-08-132017-08-03Us
RisperidoneTablet, film coated.25 mg/1OralCardinal Health2008-11-132017-05-16Us
RisperidoneTablet, film coated.5 mg/1OralAurobindo Pharma2008-10-08Not applicableUs
RisperidoneTablet.25 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2014-03-10Not applicableUs
RisperidoneTablet, orally disintegrating.5 mg/1OralZydus Pharmaceuticals Usa, Inc.2010-06-29Not applicableUs
RisperidoneTablet, film coated2 mg/1OralClinical Solutions Wholsesale2008-12-292017-06-22Us
RisperidoneTablet, film coated1 mg/1OralClinical Solutions Wholsesale2008-11-13Not applicableUs
RisperidoneTablet2 mg/1OralHikma Pharmaceutical2009-06-01Not applicableUs
RisperidoneTablet, film coated3 mg/1OralAphena Pharma Solutions Tennessee, Inc.2008-09-17Not applicableUs
RisperidoneTablet, film coated.5 mg/1OralMylan Pharmaceuticals2008-09-15Not applicableUs
RisperidoneTablet, film coated.25 mg/1OralProficient Rx LP2008-11-13Not applicableUs
RisperidoneTablet1 mg/1OralA S Medication Solutions2017-03-212017-06-20Us
RisperidoneTablet, film coated4 mg/1Oralbryant ranch prepack2008-12-29Not applicableUs00603 5688 20 nlmimage10 000e8024
RisperidoneTablet.25 mg/1OralTorrent Pharmaceuticals Limited2009-01-01Not applicableUs
RisperidoneTablet, film coated.5 mg/1OralRemedy Repack2013-03-052016-10-13Us
RisperidoneTablet2 mg/1OralTYA Pharmaceuticals2012-04-25Not applicableUs
RisperidoneTablet4 mg/1OralRemedy Repack2015-04-14Not applicableUs27241 0006 06 nlmimage10 5e41af0d
RisperidoneTablet4 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
RisperidoneTablet, film coated.5 mg/1OralContract Pharmacy Services Pa2010-12-06Not applicableUs00093 0225 06 nlmimage10 8d2946da
RisperidoneSolution1 mg/mLOralSilarx Pharmaceuticals, Inc.2015-01-30Not applicableUs
RisperidoneTablet, film coated.5 mg/1OralAmerincan Health Packaging2008-12-02Not applicableUs
RisperidoneTablet, film coated3 mg/1OralAurobindo Pharma2008-10-08Not applicableUs
RisperidoneTablet2 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2014-03-10Not applicableUs
RisperidoneTablet1 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2015-09-09Not applicableUs
RisperidoneTablet, coated.25 mg/1OralRatiopharm Inc2010-06-08Not applicableUs
RisperidoneTablet, film coated4 mg/1OralClinical Solutions Wholsesale2008-11-13Not applicableUs
RisperidoneTablet, orally disintegrating3 mg/1OralSun Pharmaceutical Industries Limited2013-04-132017-01-14Us
RisperidoneTablet1 mg/1OralSolco healthcare U.S., LLC2015-06-01Not applicableUs
RisperidoneTablet, film coated3 mg/1OralMylan Pharmaceuticals2008-09-15Not applicableUs
RisperidoneTablet, orally disintegrating4 mg/1OralRanbaxy Inc.2010-08-06Not applicableUs
RisperidoneTablet, orally disintegrating2 mg/1OralA S Medication Solutions2010-12-012017-06-20Us
RisperidoneTablet, film coated.25 mg/1OralWockhardt2008-10-09Not applicableUs
RisperidoneTablet2 mg/1OralTorrent Pharmaceuticals Limited2009-01-01Not applicableUs13668 0038 60 nlmimage10 c704e387
RisperidoneTablet, film coated.25 mg/1OralGen Source Rx2009-10-252016-03-29Us
RisperidoneTablet, orally disintegrating1 mg/1OralCadila Pharnmaceuticals2010-06-29Not applicableUs
RisperidoneTablet1 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
RisperidoneTablet, film coated3 mg/1OralContract Pharmacy Services Pa2010-12-06Not applicableUs00093 7242 06 nlmimage10 76293b69
RisperidoneTablet.25 mg/1OralPhysicians Total Care, Inc.2010-11-15Not applicableUs
RisperidoneTablet, film coated3 mg/1OralAmerincan Health Packaging2008-12-02Not applicableUs
RisperidoneTablet1 mg/1OralRebel Distributors2009-07-01Not applicableUs
RisperidoneTablet.5 mg/1OralProficient Rx LP2015-09-09Not applicableUs
RisperidoneTablet, film coated2 mg/1OralCardinal Health2010-11-122016-04-05Us
RisperidoneTablet, film coated.5 mg/1OralAv Pak2014-08-27Not applicableUs
RisperidoneTablet, film coated3 mg/1OralAurolife Pharma, LLC2009-10-25Not applicableUs
RisperidoneTablet, film coated3 mg/1OralMylan Institutional2008-10-06Not applicableUs
RisperidoneTablet, film coated2 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-072017-03-15Us
RisperidoneTablet, orally disintegrating3 mg/1OralSandoz2009-12-22Not applicableUs00781 5313 06 nlmimage10 1f3f8fec
RisperidoneTablet, orally disintegrating4 mg/1OralDr Reddy's Laboratories2009-11-30Not applicableUs
RisperidoneTablet, film coated2 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2013-06-18Not applicableUs
RisperidoneTablet, film coated.25 mg/1OralCardinal Health2010-11-122016-04-05Us
RisperidoneTablet, film coated.5 mg/1OralDr Reddy's Laboratories2009-10-24Not applicableUs
RisperidoneTablet, film coated.5 mg/1OralMc Kesson Contract Packaging2011-10-13Not applicableUs
RisperidoneTablet, orally disintegrating3 mg/1OralMylan Institutional2011-06-10Not applicableUs00378 6046 28 nlmimage10 3141988c
RisperidoneTablet, film coated1 mg/1OralQualitest2008-12-292016-09-30Us
RisperidoneSolution1 mg/mLOralTris Pharma, Inc.2012-12-122016-12-09Us
RisperidoneTablet, film coated3 mg/1OralMc Kesson Contract Packaging2012-01-03Not applicableUs
RisperidoneTablet, orally disintegrating3 mg/1OralMylan Pharmaceuticals2011-05-11Not applicableUs
RisperidoneTablet, film coated4 mg/1OralDr Reddy's Laboratories2009-10-24Not applicableUs
RisperidoneTablet, orally disintegrating.25 mg/1OralMylan Pharmaceuticals2013-03-11Not applicableUs
RisperidoneTablet, film coated4 mg/1OralRemedy Repack2010-02-152017-08-02Us
RisperidoneTablet, film coated.25 mg/1OralCardinal Health2008-10-242016-10-13Us
RisperidoneTablet1 mg/1OralRemedy Repack2015-03-122017-04-14Us
RisperidoneTablet, film coated4 mg/1OralWockhardt2008-10-09Not applicableUs
RisperidoneTablet, film coated3 mg/1OralZydus Pharmaceuticals Usa, Inc.2008-11-13Not applicableUs
RisperidoneTablet, film coated.5 mg/1OralClinical Solutions Wholsesale2008-12-292017-06-22Us
RisperidoneTablet, film coated3 mg/1OralAv Pak2014-08-27Not applicableUs
RisperidoneTablet, film coated.5 mg/1OralCobalt Laboratories2008-12-052017-02-15Us
RisperidoneTablet, film coated1 mg/1OralDirectrx2014-01-01Not applicableUs
RisperidoneTablet.5 mg/1OralHikma Pharmaceutical2009-06-01Not applicableUs
RisperidoneTablet, film coated1 mg/1OralAphena Pharma Solutions Tennessee, Inc.2008-09-17Not applicableUs
RisperidoneTablet.25 mg/1OralBreckenridge Pharmaceutical, Inc.2012-04-25Not applicableUs
RisperidoneTablet.5 mg/1OralMajor2013-11-30Not applicableUs
RisperidoneTablet, film coated1 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2008-09-17Not applicableUs
RisperidoneTablet, film coated2 mg/1OralProficient Rx LP2008-12-29Not applicableUs
RisperidoneTablet1 mg/1OralPd Rx Pharmaceuticals, Inc.2009-01-01Not applicableUs
RisperidoneTablet, film coated1 mg/1OralCardinal Health2008-10-242016-10-13Us
RisperidoneTablet3 mg/1OralAjanta Pharma Limited2015-09-09Not applicableUs
RisperidoneTablet, film coated.5 mg/1Oralbryant ranch prepack2008-12-29Not applicableUs
RisperidoneTablet, orally disintegrating2 mg/1OralJubilant Cadista Pharmaceuticals Inc.2010-12-01Not applicableUs
RisperidoneTablet, film coated.5 mg/1OralWockhardt2008-10-09Not applicableUs
RisperidoneTablet2 mg/1OralNucare Pharmaceuticals,inc.2014-03-28Not applicableUs
RisperidoneTablet3 mg/1OralBreckenridge Pharmaceutical, Inc.2012-04-25Not applicableUs51991 0320 06 nlmimage10 583f2c69
RisperidoneTablet, film coated.5 mg/1OralTYA Pharmaceuticals2008-11-13Not applicableUs
RisperidoneTablet, film coated.25 mg/1OralZydus Pharmaceuticals Usa, Inc.2008-11-13Not applicableUs
RisperidoneTablet1 mg/1OralClinical Solutions Wholsesale2009-01-01Not applicableUs
RisperidoneTablet2 mg/1OralRemedy Repack2015-03-27Not applicableUs
RisperidoneTablet2 mg/1OralH.J. Harkins Company2009-01-01Not applicableUs
RisperidoneTablet, film coated4 mg/1OralCadila Pharnmaceuticals2008-11-13Not applicableUs
RisperidoneTablet, film coated1 mg/1OralCitron Pharma LLC2008-10-08Not applicableUs
RisperidoneTablet, coated2 mg/1OralRatiopharm Inc2010-06-08Not applicableUs
RisperidoneTablet3 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
RisperidoneTablet4 mg/1OralContract Pharmacy Services Pa2010-08-25Not applicableUs
RisperidoneTablet1 mg/1OralA S Medication Solutions2013-11-302017-06-20Us
RisperidoneTablet, orally disintegrating1 mg/1OralSun Pharmaceutical Industries Limited2013-04-132017-01-14Us
RisperidoneTablet4 mg/1OralSolco healthcare U.S., LLC2015-06-01Not applicableUs
RisperidoneTablet, film coated4 mg/1OralCobalt Laboratories2008-12-052017-02-15Us
RisperidoneTablet1 mg/1OralAjanta Pharma Limited2015-09-09Not applicableUs
RisperidoneTablet, orally disintegrating2 mg/1OralRanbaxy Inc.2010-08-06Not applicableUs
RisperidoneTablet2 mg/1OralApotex Corporation2008-09-22Not applicableUs
RisperidoneTablet, orally disintegrating1 mg/1OralPar Pharmaceutical2009-10-26Not applicableUs
RisperidoneTablet, film coated2 mg/1OralWockhardt2008-10-09Not applicableUs
RisperidoneTablet1 mg/1OralCardinal Health2013-11-30Not applicableUs
RisperidoneTablet, film coated2 mg/1OralGen Source Rx2009-10-252016-03-29Us
RisperidoneTablet, film coated.5 mg/1OralCadila Pharnmaceuticals2008-11-13Not applicableUs
RisperidoneTablet, film coated.5 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
RisperidoneTablet.5 mg/1OralContract Pharmacy Services Pa2010-08-25Not applicableUs
RisperidoneTablet3 mg/1OralRemedy Repack2011-05-05Not applicableUs
RisperidoneTablet4 mg/1OralMajor2013-11-30Not applicableUs
RisperidoneTablet.5 mg/1OralTorrent Pharmaceuticals Limited2009-01-01Not applicableUs
RisperidoneTablet, film coated.5 mg/1OralRemedy Repack2013-03-182016-04-05Us
RisperidoneTablet4 mg/1OralTYA Pharmaceuticals2012-04-25Not applicableUs
RisperidoneTablet1 mg/1OralRemedy Repack2015-12-24Not applicableUs
RisperidoneTablet, film coated2 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
RisperidoneTablet, film coated1 mg/1OralContract Pharmacy Services Pa2010-12-06Not applicableUs00093 7240 06 nlmimage10 7f293fe9
RisperidoneTablet1 mg/1OralPhysicians Total Care, Inc.2008-07-23Not applicableUs
RisperidoneTablet, film coated1 mg/1OralAmerincan Health Packaging2008-12-02Not applicableUs
RisperidoneTablet.25 mg/1OralRebel Distributors2009-07-01Not applicableUs
RisperidoneTablet, film coated1 mg/1OralCardinal Health2012-09-19Not applicableUs
RisperidoneTablet, film coated4 mg/1OralRemedy Repack2013-05-012016-10-25Us68382 0112 14 nlmimage10 4c3d2629
RisperidoneTablet, film coated1 mg/1OralAurolife Pharma, LLC2009-10-25Not applicableUs
RisperidoneTablet, film coated1 mg/1OralMylan Institutional2008-10-06Not applicableUs
RisperidoneTablet, film coated3 mg/1OralQualitest2008-12-292016-08-31Us
RisperidoneTablet, orally disintegrating1 mg/1OralSandoz2009-12-22Not applicableUs
RisperidoneTablet, orally disintegrating2 mg/1OralDr Reddy's Laboratories2009-02-24Not applicableUs
RisperidoneTablet, film coated3 mg/1OralRemedy Repack2013-05-012017-02-14Us
RisperidoneTablet, film coated.5 mg/1OralCardinal Health2008-11-132017-05-16Us68382 0113 05 nlmimage10 553d2ad9
RisperidoneTablet, film coated1 mg/1OralAurobindo Pharma2008-10-08Not applicableUs
RisperidoneTablet.5 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2014-03-10Not applicableUs
RisperidoneTablet, orally disintegrating1 mg/1OralZydus Pharmaceuticals Usa, Inc.2010-06-29Not applicableUs
RisperidoneTablet, film coated4 mg/1OralClinical Solutions Wholsesale2008-12-292017-06-22Us
RisperidoneTablet, film coated2 mg/1OralClinical Solutions Wholsesale2008-11-13Not applicableUs
RisperidoneTablet3 mg/1OralHikma Pharmaceutical2009-06-01Not applicableUs
RisperidoneTablet.25 mg/1OralSolco healthcare U.S., LLC2015-06-01Not applicableUs
RisperidoneTablet, film coated1 mg/1OralMylan Pharmaceuticals2008-09-15Not applicableUs
RisperidoneTablet2 mg/1OralProficient Rx LP2014-04-23Not applicableUs
RisperidoneTablet1 mg/1OralRemedy Repack2017-03-27Not applicableUs
RisperidoneTablet, film coated1 mg/1OralMc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation2012-02-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
RisperdalNot Available
Risperidal M-TabJanssen
RisperinNot Available
RispoleptNot Available
RispolinNot Available
SequinanNot Available
Brand mixturesNot Available
Categories
UNIIL6UH7ZF8HC
CAS number106266-06-2
WeightAverage: 410.4845
Monoisotopic: 410.211804333
Chemical FormulaC23H27FN4O2
InChI KeyRAPZEAPATHNIPO-UHFFFAOYSA-N
InChI
InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3
IUPAC Name
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidin-4-one
SMILES
CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
Pharmacology
Indication

For the treatment of schizophrenia in adults and in adolescents, ages 13 to 17, and for the short-term treatment of manic or mixed episodes of bipolar I disorder in children and adolescents ages 10 to 17. May also be used to manage symptoms of inappropriate behavior due to aggression and/or psychosis in patients with severe dementia.

Structured Indications
Pharmacodynamics

Risperidone is an atypical antipsychotic medication. It is most often used to treat delusional psychosis (including schizophrenia), but risperidone is also used to treat some forms of bipolar disorder and psychotic depression. It also has shown some success in treating symptoms of Asperger's Syndrome and autism. Risperidone is now the most commonly prescribed antipsychotic medication in the United States.

Mechanism of action

Blockade of dopaminergic D2 receptors in the limbic system alleviates positive symptoms of schizophrenia such as hallucinations, delusions, and erratic behavior and speech. Blockade of serotonergic 5-HT2 receptors in the mesocortical tract, causes an excess of dopamine and an increase in dopamine transmission, resulting in an increase in dopamine transmission and an elimination of core negative symptoms. Dopamine receptors in the nigrostriatal pathway are not affected by risperidone and extrapyramidal effects are avoided. Like other 5-HT2 antagonists, risperidone also binds at alpha(1)-adrenergic receptors and, to a lesser extent, at histamine H1 and alpha(2)-adrenergic receptors.

TargetKindPharmacological actionActionsOrganismUniProt ID
5-hydroxytryptamine receptor 2AProteinyes
antagonist
HumanP28223 details
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
D(3) dopamine receptorProteinunknown
antagonist
HumanP35462 details
D(4) dopamine receptorProteinunknown
antagonist
HumanP21917 details
Alpha-1A adrenergic receptorProteinunknown
antagonist
HumanP35348 details
Alpha-1B adrenergic receptorProteinunknown
antagonist
HumanP35368 details
5-hydroxytryptamine receptor 1DProteinunknown
antagonist
HumanP28221 details
Histamine H1 receptorProteinunknown
antagonist
HumanP35367 details
Alpha-2A adrenergic receptorProteinunknown
antagonist
HumanP08913 details
Alpha-2B adrenergic receptorProteinunknown
antagonist
agonist
HumanP18089 details
Alpha-2C adrenergic receptorProteinunknown
agonist
HumanP18825 details
5-hydroxytryptamine receptor 2CProteinunknown
antagonist
HumanP28335 details
5-hydroxytryptamine receptor 1AProteinunknown
antagonist
HumanP08908 details
D(1A) dopamine receptorProteinunknown
antagonist
HumanP21728 details
5-hydroxytryptamine receptor 7ProteinunknownNot AvailableHumanP34969 details
Related Articles
Absorption

Well absorbed. The absolute oral bioavailability of risperidone is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution.

Volume of distribution
  • 1 to 2 L/kg
Protein binding

Risperidone, ~88% bound; 9-hydroxyrisperidone, ~77% bound.

Metabolism

Extensively metabolized by hepatic cytochrome P450 2D6 isozyme to 9-hydroxyrisperidone, which has approximately the same receptor binding affinity as risperidone. Hydroxylation is dependent on debrisoquine 4-hydroxylase and metabolism is sensitive to genetic polymorphisms in debrisoquine 4-hydroxylase. Risperidone also undergoes N-dealkylation to a lesser extent.

SubstrateEnzymesProduct
Risperidone
9-hydroxyrisperidoneDetails
Route of elimination

Risperidone is extensively metabolized in the liver.In healthy elderly subjects, renal clearance of both risperidone and 9-hydroxyrisperidone was decreased, and elimination half-lives were prolonged compared to young healthy subjects.

Half life

20-24 hours

ClearanceNot Available
Toxicity

Symptoms of overdose include drowsiness, sedation, tachycardia, hypotension, and extrapyramidal symptoms. LD50=82.1mg/kg (orally in mice).

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Risperidone.Investigational
2,5-Dimethoxy-4-ethylamphetamineRisperidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineRisperidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineRisperidone may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineRisperidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Risperidone is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Risperidone can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Risperidone.Approved, Investigational
AcebutololAcebutolol may increase the hypotensive activities of Risperidone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Risperidone can be increased when it is combined with Acetaminophen.Approved
AcetazolamideAcetazolamide may increase the hypotensive activities of Risperidone.Approved, Vet Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Risperidone.Withdrawn
AdipiplonThe risk or severity of adverse effects can be increased when Risperidone is combined with adipiplon.Investigational
AfatinibThe serum concentration of Risperidone can be increased when it is combined with Afatinib.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Risperidone is combined with Agomelatine.Approved, Investigational
AICA ribonucleotideThe therapeutic efficacy of Aicar can be decreased when used in combination with Risperidone.Experimental
AlbendazoleThe serum concentration of Risperidone can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinAldesleukin may increase the hypotensive activities of Risperidone.Approved
AldosteroneThe serum concentration of Risperidone can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Risperidone can be increased when it is combined with Alectinib.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Risperidone is combined with Alfaxalone.Vet Approved
AlfentanilThe serum concentration of Risperidone can be increased when it is combined with Alfentanil.Approved, Illicit
AliskirenAliskiren may increase the hypotensive activities of Risperidone.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Risperidone is combined with Sage 547.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Risperidone.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Risperidone.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Risperidone is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Risperidone.Approved, Illicit, Investigational
AlprenololRisperidone may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AmantadineThe therapeutic efficacy of Amantadine can be decreased when used in combination with Risperidone.Approved
AmifostineAmifostine may increase the hypotensive activities of Risperidone.Approved, Investigational
AmilorideAmiloride may increase the hypotensive activities of Risperidone.Approved
AmineptineAmineptine may decrease the antihypertensive activities of Risperidone.Illicit, Withdrawn
Aminohippuric acidThe serum concentration of Risperidone can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneAmiodarone may increase the hypotensive activities of Risperidone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Risperidone is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Risperidone.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Risperidone.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Risperidone is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Risperidone is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Risperidone is combined with Amperozide.Experimental
AmphetamineRisperidone may decrease the stimulatory activities of Amphetamine.Approved, Illicit
Amphotericin BAmphotericin B may increase the hypotensive activities of Risperidone.Approved, Investigational
AmprenavirThe serum concentration of Risperidone can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Risperidone can be increased when it is combined with Amsacrine.Approved
Amyl NitriteAmyl Nitrite may increase the hypotensive activities of Risperidone.Approved
AnagrelideRisperidone may increase the QTc-prolonging activities of Anagrelide.Approved
ApomorphineApomorphine may increase the hypotensive activities of Risperidone.Approved, Investigational
ApraclonidineApraclonidine may increase the hypotensive activities of Risperidone.Approved
AprepitantThe serum concentration of Risperidone can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Risperidone.Approved, Investigational
ArotinololArotinolol may increase the hypotensive activities of Risperidone.Approved
Arsenic trioxideArsenic trioxide may increase the hypotensive activities of Risperidone.Approved, Investigational
ArtemetherRisperidone may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Articaine.Approved
AsenapineRisperidone may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe serum concentration of Risperidone can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Risperidone can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Risperidone.Approved
AtomoxetineThe metabolism of Risperidone can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Risperidone can be increased when it is combined with Atorvastatin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Azaperone.Vet Approved
AzelastineRisperidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe serum concentration of Risperidone can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilAzilsartan medoxomil may increase the hypotensive activities of Risperidone.Approved
AzithromycinRisperidone may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Risperidone is combined with Baclofen.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Risperidone.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Risperidone is combined with Barbital.Illicit
BarnidipineBarnidipine may increase the hypotensive activities of Risperidone.Approved
BedaquilineRisperidone may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololRisperidone may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BenazeprilBenazepril may increase the hypotensive activities of Risperidone.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Risperidone.Approved
BenperidolThe risk or severity of adverse effects can be increased when Risperidone is combined with Benperidol.Investigational
BenzocaineThe serum concentration of Risperidone can be increased when it is combined with Benzocaine.Approved
BenzphetamineRisperidone may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Risperidone is combined with Benzyl alcohol.Approved
BepridilBepridil may increase the hypotensive activities of Risperidone.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Risperidone.Approved
BevantololRisperidone may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BexaroteneThe serum concentration of Risperidone can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Risperidone can be increased when it is combined with Biperiden.Approved
BisoprololBisoprolol may increase the hypotensive activities of Risperidone.Approved
BoceprevirThe metabolism of Risperidone can be decreased when combined with Boceprevir.Withdrawn
BopindololRisperidone may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BortezomibBortezomib may increase the hypotensive activities of Risperidone.Approved, Investigational
BosentanThe serum concentration of Risperidone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Risperidone can be increased when it is combined with Bosutinib.Approved
BretyliumBretylium may increase the hypotensive activities of Risperidone.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Risperidone is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the hypotensive activities of Risperidone.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Bromazepam.Approved, Illicit
BromocriptineBromocriptine may increase the hypotensive activities of Risperidone.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Risperidone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Risperidone is combined with Brotizolam.Approved, Withdrawn
BucindololRisperidone may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Risperidone.Withdrawn
BufuralolRisperidone may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Risperidone.Approved
BupivacaineBupivacaine may increase the hypotensive activities of Risperidone.Approved, Investigational
BupranololRisperidone may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BuprenorphineRisperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Risperidone can be decreased when combined with Bupropion.Approved
BuspironeThe serum concentration of Risperidone can be increased when it is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Risperidone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Risperidone is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Risperidone is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Risperidone is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Risperidone.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Risperidone can be increased when it is combined with Cabazitaxel.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Risperidone.Approved
CaffeineThe serum concentration of Risperidone can be increased when it is combined with Caffeine.Approved
CanagliflozinCanagliflozin may increase the hypotensive activities of Risperidone.Approved
CandesartanCandesartan may increase the hypotensive activities of Risperidone.Approved
CaptoprilCaptopril may increase the hypotensive activities of Risperidone.Approved
CarbamazepineThe serum concentration of Risperidone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbetocinCarbetocin may increase the hypotensive activities of Risperidone.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Risperidone is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Risperidone is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Risperidone is combined with Carisoprodol.Approved
CarteololCarteolol may increase the hypotensive activities of Risperidone.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Risperidone.Approved, Investigational
CaspofunginThe serum concentration of Risperidone can be increased when it is combined with Caspofungin.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Risperidone.Experimental
CelecoxibThe metabolism of Risperidone can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololRisperidone may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Risperidone can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Risperidone is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Risperidone is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Risperidone.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Chloroprocaine.Approved
ChloroquineRisperidone may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Risperidone.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Risperidone is combined with Chlorphenamine.Approved
ChlorphentermineRisperidone may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineChlorpromazine may increase the hypotensive activities of Risperidone.Approved, Vet Approved
ChlorpropamideThe serum concentration of Risperidone can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Risperidone can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Risperidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Risperidone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Risperidone can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Risperidone can be decreased when it is combined with Cholic Acid.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Risperidone.Experimental
CilazaprilCilazapril may increase the hypotensive activities of Risperidone.Approved
CilnidipineCilnidipine may increase the hypotensive activities of Risperidone.Approved
CimetidineThe serum concentration of Risperidone can be decreased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Risperidone can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Risperidone.Approved, Vet Approved
CiprofloxacinRisperidone may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideRisperidone may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Risperidone can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Risperidone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Risperidone can be decreased when combined with Clemastine.Approved
ClevidipineClevidipine may increase the hypotensive activities of Risperidone.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Risperidone is combined with Clidinium.Approved
ClobazamThe metabolism of Risperidone can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineClofarabine may increase the hypotensive activities of Risperidone.Approved, Investigational
ClofazimineThe serum concentration of Risperidone can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Risperidone is combined with clomethiazole.Investigational
ClomipramineClomipramine may increase the hypotensive activities of Risperidone.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Clonazepam.Approved, Illicit
ClonidineClonidine may increase the hypotensive activities of Risperidone.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Risperidone.Approved, Illicit
ClotrimazoleThe metabolism of Risperidone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the hypotensive activities of Risperidone.Approved
CobicistatThe serum concentration of Risperidone can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Risperidone can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Risperidone.Approved, Illicit
ColchicineThe serum concentration of Risperidone can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Risperidone can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Risperidone can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibRisperidone may increase the QTc-prolonging activities of Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Risperidone is combined with Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may decrease the antihypertensive activities of Risperidone.Approved
CyclophosphamideThe serum concentration of Risperidone can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Risperidone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Risperidone is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Risperidone can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Risperidone can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Risperidone can be increased when it is combined with Dactinomycin.Approved
DantroleneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dantrolene.Approved
DapagliflozinDapagliflozin may increase the hypotensive activities of Risperidone.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Risperidone.Approved
DapoxetineThe metabolism of Risperidone can be decreased when combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Risperidone can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Risperidone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Risperidone can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Risperidone can be decreased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Risperidone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Risperidone can be decreased when combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Risperidone.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Risperidone is combined with deramciclane.Investigational
DesfluraneDesflurane may increase the hypotensive activities of Risperidone.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Risperidone.Approved
DesloratadineThe serum concentration of Risperidone can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe metabolism of Risperidone can be decreased when combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Risperidone is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Risperidone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Risperidone is combined with Dexbrompheniramine.Approved
DexmedetomidineDexmedetomidine may increase the hypotensive activities of Risperidone.Approved, Vet Approved
DextroamphetamineRisperidone may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe serum concentration of Risperidone can be increased when it is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Risperidone is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Risperidone.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Risperidone is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Diazepam.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Risperidone can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideDiclofenamide may increase the hypotensive activities of Risperidone.Approved
DiethylpropionRisperidone may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Risperidone is combined with Difenoxin.Approved, Illicit
DigoxinThe serum concentration of Risperidone can be decreased when it is combined with Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Risperidone is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Risperidone can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Risperidone is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Risperidone is combined with Dihydromorphine.Experimental, Illicit
DiltiazemDiltiazem may increase the hypotensive activities of Risperidone.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Risperidone is combined with Dimenhydrinate.Approved
DinutuximabDinutuximab may increase the hypotensive activities of Risperidone.Approved
DiphenhydramineThe metabolism of Risperidone can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Risperidone is combined with Diphenoxylate.Approved, Illicit
DipyridamoleDipyridamole may increase the hypotensive activities of Risperidone.Approved
DisopyramideRisperidone may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideRisperidone may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronRisperidone may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneRisperidone may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Risperidone is combined with Doramectin.Vet Approved
DosulepinDosulepin may decrease the antihypertensive activities of Risperidone.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Risperidone.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Risperidone.Approved
DoxorubicinThe serum concentration of Risperidone can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Risperidone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Risperidone is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved, Illicit
DronedaroneRisperidone may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Risperidone is combined with Drotebanol.Experimental, Illicit
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Risperidone.Approved
DuloxetineThe metabolism of Risperidone can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Risperidone.Approved
EcgonineThe risk or severity of adverse effects can be increased when Risperidone is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Risperidone is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Risperidone can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineEfonidipine may increase the hypotensive activities of Risperidone.Approved
ElbasvirThe serum concentration of Risperidone can be increased when it is combined with Elbasvir.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Risperidone.Approved, Investigational
EliglustatRisperidone may increase the QTc-prolonging activities of Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Risperidone is combined with Pregnanolone.Investigational
EmpagliflozinEmpagliflozin may increase the hypotensive activities of Risperidone.Approved
EnalaprilEnalapril may increase the hypotensive activities of Risperidone.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hypotensive activities of Risperidone.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Risperidone.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Risperidone is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Risperidone can be decreased when it is combined with Enzalutamide.Approved
EplerenoneEplerenone may increase the hypotensive activities of Risperidone.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Risperidone.Approved
EprosartanEprosartan may increase the hypotensive activities of Risperidone.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Risperidone.Approved
ErgonovineThe serum concentration of Risperidone can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Risperidone can be increased when it is combined with Ergotamine.Approved
ErythromycinRisperidone may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramThe metabolism of Risperidone can be decreased when combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Risperidone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Risperidone.Investigational
EsmololEsmolol may increase the hypotensive activities of Risperidone.Approved
EstazolamThe risk or severity of adverse effects can be increased when Risperidone is combined with Estazolam.Approved, Illicit
EstramustineThe serum concentration of Risperidone can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Risperidone can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Risperidone can be decreased when it is combined with Estrone.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Risperidone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Risperidone.Approved
EthanolRisperidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Risperidone.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Risperidone is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Risperidone is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Risperidone.Approved
EtoperidoneThe metabolism of Risperidone can be decreased when combined with Etoperidone.Approved
EtoposideThe serum concentration of Risperidone can be increased when it is combined with Etoposide.Approved
EtorphineThe risk or severity of adverse effects can be increased when Risperidone is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Risperidone can be decreased when it is combined with Etravirine.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Risperidone.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Risperidone is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Risperidone is combined with Felbamate.Approved
FelodipineFelodipine may increase the hypotensive activities of Risperidone.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Risperidone is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamFenoldopam may increase the hypotensive activities of Risperidone.Approved
FentanylThe serum concentration of Risperidone can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Risperidone.Approved
FexofenadineThe serum concentration of Risperidone can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Risperidone can be increased when it is combined with Fidaxomicin.Approved
FimasartanFimasartan may increase the hypotensive activities of Risperidone.Approved
FlecainideRisperidone may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Risperidone is combined with Flibanserin.Approved
FluconazoleThe metabolism of Risperidone can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Risperidone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Risperidone can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolRisperidone may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Risperidone can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Risperidone can be increased when it is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Risperidone is combined with Fluspirilene.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Risperidone is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Risperidone can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Risperidone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Risperidone can be increased when it is combined with Fosaprepitant.Approved
FosinoprilFosinopril may increase the hypotensive activities of Risperidone.Approved
FosphenytoinThe metabolism of Risperidone can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Risperidone is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Risperidone.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Risperidone.Approved, Vet Approved
Fusidic AcidThe serum concentration of Risperidone can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Risperidone is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Risperidone is combined with gabapentin enacarbil.Approved
Gadobenic acidRisperidone may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Risperidone is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Risperidone can be increased when it is combined with Gefitinib.Approved, Investigational
GemifloxacinRisperidone may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Risperidone can be increased when it is combined with Genistein.Investigational
GepironeThe risk or severity of adverse effects can be increased when Risperidone is combined with Gepirone.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Risperidone.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Risperidone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Risperidone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Risperidone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Risperidone.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Risperidone is combined with Glutethimide.Approved, Illicit
GlyburideThe serum concentration of Risperidone can be increased when it is combined with Glyburide.Approved
GoserelinRisperidone may increase the QTc-prolonging activities of Goserelin.Approved
Gramicidin DThe serum concentration of Risperidone can be increased when it is combined with Gramicidin D.Approved
GranisetronRisperidone may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrepafloxacinThe serum concentration of Risperidone can be increased when it is combined with Grepafloxacin.Withdrawn
GuanfacineGuanfacine may increase the hypotensive activities of Risperidone.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Risperidone.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolRisperidone may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneHalothane may increase the hypotensive activities of Risperidone.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Risperidone is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Risperidone is combined with Hexobarbital.Approved
HydralazineHydralazine may increase the hypotensive activities of Risperidone.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Risperidone.Approved, Vet Approved
HydrocodoneRisperidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Risperidone can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Risperidone.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Risperidone.Approved, Illicit
HydroxyamphetamineRisperidone may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved
IbutilideRisperidone may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Risperidone can be increased when it is combined with Idelalisib.Approved
IloperidoneRisperidone may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostIloprost may increase the hypotensive activities of Risperidone.Approved, Investigational
ImatinibThe metabolism of Risperidone can be decreased when combined with Imatinib.Approved
ImidaprilImidapril may increase the hypotensive activities of Risperidone.Investigational
ImipramineImipramine may increase the hypotensive activities of Risperidone.Approved
IndalpineThe metabolism of Risperidone can be decreased when combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the hypotensive activities of Risperidone.Approved
IndenololRisperidone may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndinavirThe metabolism of Risperidone can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Risperidone can be increased when it is combined with Indomethacin.Approved, Investigational
IndoraminIndoramin may increase the hypotensive activities of Risperidone.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Risperidone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Risperidone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Risperidone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Risperidone.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Risperidone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Risperidone.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Risperidone.Approved
IrbesartanIrbesartan may increase the hypotensive activities of Risperidone.Approved, Investigational
IsavuconazoniumThe metabolism of Risperidone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Risperidone.Approved
IsofluraneIsoflurane may increase the hypotensive activities of Risperidone.Approved, Vet Approved
IsoniazidThe metabolism of Risperidone can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateIsosorbide Dinitrate may increase the hypotensive activities of Risperidone.Approved
Isosorbide MononitrateIsosorbide Mononitrate may increase the hypotensive activities of Risperidone.Approved
IsoxsuprineIsoxsuprine may increase the hypotensive activities of Risperidone.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Risperidone.Approved
ItraconazoleThe metabolism of Risperidone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Risperidone can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Risperidone can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Risperidone can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Risperidone is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Risperidone can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolLabetalol may increase the hypotensive activities of Risperidone.Approved
LacidipineLacidipine may increase the hypotensive activities of Risperidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Risperidone is combined with Lamotrigine.Approved, Investigational
LandiololRisperidone may increase the atrioventricular blocking (AV block) activities of Aop200704.Investigational
LansoprazoleThe serum concentration of Risperidone can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Risperidone can be increased when it is combined with Lapatinib.Approved, Investigational
LenvatinibRisperidone may increase the QTc-prolonging activities of Lenvatinib.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Risperidone.Approved, Investigational
LeuprolideRisperidone may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Risperidone is combined with Levetiracetam.Approved, Investigational
LevobunololLevobunolol may increase the hypotensive activities of Risperidone.Approved
LevobupivacaineLevobupivacaine may increase the hypotensive activities of Risperidone.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Risperidone is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Risperidone is combined with Levocetirizine.Approved
LevodopaLevodopa may increase the hypotensive activities of Risperidone.Approved
LevofloxacinRisperidone may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Risperidone is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe metabolism of Risperidone can be decreased when combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Risperidone is combined with Levorphanol.Approved
LevosimendanLevosimendan may increase the hypotensive activities of Risperidone.Approved, Investigational
LevothyroxineThe serum concentration of Risperidone can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Risperidone can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Risperidone.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Risperidone.Approved, Investigational
LiothyronineThe serum concentration of Risperidone can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Risperidone can be decreased when it is combined with Liotrix.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Risperidone.Approved
LisdexamfetamineRisperidone may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilLisinopril may increase the hypotensive activities of Risperidone.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Risperidone.Approved
LofentanilThe risk or severity of adverse effects can be increased when Risperidone is combined with Lofentanil.Illicit
LofexidineLofexidine may increase the hypotensive activities of Risperidone.Approved, Investigational
LomitapideThe serum concentration of Risperidone can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Risperidone can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Risperidone can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Risperidone can be increased when it is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Risperidone.Approved
LorcaserinThe metabolism of Risperidone can be decreased when combined with Lorcaserin.Approved
LosartanLosartan may increase the hypotensive activities of Risperidone.Approved
LovastatinThe metabolism of Risperidone can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Risperidone.Approved
LuliconazoleThe serum concentration of Risperidone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Risperidone can be decreased when it is combined with Lumacaftor.Approved
LumefantrineRisperidone may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved, Vet Approved
MannitolMannitol may increase the hypotensive activities of Risperidone.Approved, Investigational
MaprotilineThe serum concentration of Risperidone can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Risperidone can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineMecamylamine may increase the hypotensive activities of Risperidone.Approved
MeclizineThe risk or severity of adverse effects can be increased when Risperidone is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Risperidone is combined with Medetomidine.Vet Approved
MefloquineThe serum concentration of Risperidone can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Risperidone can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Risperidone is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Melperone.Approved
MephedroneRisperidone may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineRisperidone may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe serum concentration of Risperidone can be increased when it is combined with Meprobamate.Approved, Illicit
MequitazineRisperidone may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Risperidone is combined with Metaxalone.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Risperidone.Approved
MethadoneRisperidone may increase the QTc-prolonging activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Risperidone is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineRisperidone may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methaqualone.Illicit, Withdrawn
MethazolamideMethazolamide may increase the hypotensive activities of Risperidone.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Risperidone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Risperidone.Approved
MethotrimeprazineRisperidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Risperidone is combined with Methsuximide.Approved
MethyclothiazideMethyclothiazide may increase the hypotensive activities of Risperidone.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Risperidone.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Risperidone is combined with ECGONINE METHYL ESTER.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Risperidone is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Risperidone is combined with Methylphenobarbital.Approved
MetipranololMetipranolol may increase the hypotensive activities of Risperidone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Risperidone.Approved, Investigational
MetolazoneMetolazone may increase the hypotensive activities of Risperidone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Risperidone.Approved, Investigational
MetyrosineRisperidone may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Risperidone can be decreased when used in combination with Mianserin.Approved
MibefradilThe serum concentration of Risperidone can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Risperidone can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Risperidone can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Risperidone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Risperidone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Risperidone.Approved
MilnacipranThe metabolism of Risperidone can be decreased when combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved, Investigational
MinoxidilMinoxidil may increase the hypotensive activities of Risperidone.Approved
MirabegronThe metabolism of Risperidone can be decreased when combined with Mirabegron.Approved
MirtazapineMirtazapine may decrease the antihypertensive activities of Risperidone.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Risperidone.Approved, Investigational
MitomycinThe serum concentration of Risperidone can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Risperidone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Risperidone can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MMDARisperidone may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Risperidone.Approved
ModafinilThe serum concentration of Risperidone can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Risperidone.Approved
MolindoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Molindone.Approved
MorphineMorphine may increase the hypotensive activities of Risperidone.Approved, Investigational
MoxifloxacinRisperidone may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Risperidone.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved, Investigational
NadololNadolol may increase the hypotensive activities of Risperidone.Approved
NafcillinThe serum concentration of Risperidone can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Risperidone is combined with Nalbuphine.Approved
NaltrexoneThe serum concentration of Risperidone can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Risperidone.Approved, Investigational
NaringeninThe serum concentration of Risperidone can be increased when it is combined with Naringenin.Experimental
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Risperidone.Approved, Investigational
NebivololNebivolol may increase the hypotensive activities of Risperidone.Approved, Investigational
NefazodoneThe metabolism of Risperidone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Risperidone can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Risperidone can be increased when it is combined with Neostigmine.Approved, Vet Approved
NesiritideNesiritide may increase the hypotensive activities of Risperidone.Approved, Investigational
NetupitantThe serum concentration of Risperidone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Risperidone can be increased when combined with Nevirapine.Approved
NicardipineNicardipine may increase the hypotensive activities of Risperidone.Approved
NifedipineNifedipine may increase the hypotensive activities of Risperidone.Approved
NilotinibRisperidone may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineNilvadipine may increase the hypotensive activities of Risperidone.Approved
NimodipineNimodipine may increase the hypotensive activities of Risperidone.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Risperidone.Approved
NitrazepamThe serum concentration of Risperidone can be increased when it is combined with Nitrazepam.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Risperidone.Approved
Nitric OxideNitric Oxide may increase the hypotensive activities of Risperidone.Approved
NitroglycerinNitroglycerin may increase the hypotensive activities of Risperidone.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Risperidone.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Risperidone is combined with Nitrous oxide.Approved, Vet Approved
NorethisteroneThe serum concentration of Risperidone can be decreased when it is combined with Norethisterone.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Risperidone is combined with 1,1,1,2 Tetrafluoroethane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may decrease the antihypertensive activities of Risperidone.Approved
ObinutuzumabObinutuzumab may increase the hypotensive activities of Risperidone.Approved
OfloxacinRisperidone may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Risperidone.Approved, Investigational
OlaparibThe metabolism of Risperidone can be decreased when combined with Olaparib.Approved
OlmesartanOlmesartan may increase the hypotensive activities of Risperidone.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Risperidone is combined with Olopatadine.Approved
OmeprazoleThe serum concentration of Risperidone can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronRisperidone may increase the QTc-prolonging activities of Ondansetron.Approved
OpipramolOpipramol may decrease the antihypertensive activities of Risperidone.Investigational
OpiumThe risk or severity of adverse effects can be increased when Risperidone is combined with Opium.Approved, Illicit
OrphenadrineRisperidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Risperidone is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Risperidone can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Oxazepam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Oxetacaine.Investigational
OxprenololOxprenolol may increase the hypotensive activities of Risperidone.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Risperidone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Oxymorphone.Approved, Investigational, Vet Approved
P-NitrophenolThe serum concentration of Risperidone can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelPaclitaxel may increase the hypotensive activities of Risperidone.Approved, Vet Approved
PalbociclibThe serum concentration of Risperidone can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Paliperidone.Approved
Palmitic AcidThe serum concentration of Risperidone can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Risperidone can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Risperidone can be increased when it is combined with Pantoprazole.Approved
PapaverinePapaverine may increase the hypotensive activities of Risperidone.Approved
ParaldehydeRisperidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Risperidone can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibRisperidone may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Risperidone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the hypotensive activities of Risperidone.Approved, Investigational
PentamidineRisperidone may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Risperidone.Approved, Vet Approved
PentobarbitalThe metabolism of Risperidone can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved
PerazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Perazine.Investigational
PerflutrenRisperidone may increase the QTc-prolonging activities of Perflutren.Approved
PerindoprilPerindopril may increase the hypotensive activities of Risperidone.Approved
PerospironeThe risk or severity of adverse effects can be increased when Risperidone is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Risperidone.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Risperidone.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Risperidone.Approved, Withdrawn
PhenobarbitalThe metabolism of Risperidone can be increased when combined with Phenobarbital.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Risperidone.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Risperidone is combined with Phenoxyethanol.Approved
PhentermineRisperidone may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolaminePhentolamine may increase the hypotensive activities of Risperidone.Approved
PhenytoinThe metabolism of Risperidone can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideRisperidone may increase the QTc-prolonging activities of Pimozide.Approved
PindololPindolol may increase the hypotensive activities of Risperidone.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Risperidone.Approved, Investigational
PipamperonePipamperone may increase the hypotensive activities of Risperidone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Pipotiazine.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Risperidone.Experimental
PiribedilThe therapeutic efficacy of Piribedil can be decreased when used in combination with Risperidone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Risperidone is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Risperidone is combined with Pizotifen.Approved
Platelet Activating FactorThe serum concentration of Risperidone can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe risk or severity of adverse effects can be increased when Risperidone is combined with Pomalidomide.Approved
PonatinibThe serum concentration of Risperidone can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe metabolism of Risperidone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololRisperidone may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PramipexoleRisperidone may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Risperidone.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Pramocaine.Approved
PravastatinThe serum concentration of Risperidone can be increased when it is combined with Pravastatin.Approved
PrazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Prazepam.Approved, Illicit
PrazosinPrazosin may increase the hypotensive activities of Risperidone.Approved
PrednisoneThe serum concentration of Risperidone can be increased when it is combined with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Risperidone.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Prilocaine.Approved
PrimaquineRisperidone may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Risperidone can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Risperidone can be increased when it is combined with Probenecid.Approved
ProcainamideRisperidone may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Risperidone.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Risperidone.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Risperidone.Approved, Vet Approved
ProgesteroneThe serum concentration of Risperidone can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineRisperidone may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Risperidone can be increased when it is combined with Promethazine.Approved
PropafenoneRisperidone may increase the QTc-prolonging activities of Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Proparacaine.Approved, Vet Approved
PropofolPropofol may increase the hypotensive activities of Risperidone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Propoxycaine.Approved
PropranololPropranolol may increase the hypotensive activities of Risperidone.Approved, Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Risperidone.Approved
PSD502The risk or severity of adverse effects can be increased when Risperidone is combined with PSD502.Investigational
PseudoephedrineRisperidone may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Quazepam.Approved, Illicit
QuercetinThe serum concentration of Risperidone can be increased when it is combined with Quercetin.Experimental
QuetiapineQuetiapine may increase the hypotensive activities of Risperidone.Approved
QuinacrineThe serum concentration of Risperidone can be increased when it is combined with Quinacrine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Risperidone.Approved
QuinaprilQuinapril may increase the hypotensive activities of Risperidone.Approved, Investigational
QuinidineRisperidone may increase the QTc-prolonging activities of Quinidine.Approved
QuinineRisperidone may increase the QTc-prolonging activities of Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Risperidone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Risperidone is combined with Ramelteon.Approved, Investigational
RamiprilRamipril may increase the hypotensive activities of Risperidone.Approved
RanitidineThe serum concentration of Risperidone can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Risperidone can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Risperidone.Approved
ReboxetineThe serum concentration of Risperidone can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Risperidone can be increased when it is combined with Regorafenib.Approved
RemifentanilRemifentanil may increase the hypotensive activities of Risperidone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Risperidone.Approved, Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Risperidone.Approved, Investigational
ReserpineReserpine may increase the hypotensive activities of Risperidone.Approved
RifabutinThe metabolism of Risperidone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Risperidone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Risperidone can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Risperidone can be increased when it is combined with Rilpivirine.Approved
RiociguatRiociguat may increase the hypotensive activities of Risperidone.Approved
RitanserinThe risk or severity of adverse effects can be increased when Risperidone is combined with Ritanserin.Investigational
RitobegronRisperidone may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe metabolism of Risperidone can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Risperidone.Approved
RolapitantThe serum concentration of Risperidone can be increased when it is combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Risperidone is combined with Romifidine.Vet Approved
RopiniroleRisperidone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineRopivacaine may increase the hypotensive activities of Risperidone.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Risperidone.Approved, Investigational
RotigotineRisperidone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Risperidone.Approved
SacubitrilSacubitril may increase the hypotensive activities of Risperidone.Approved
SaquinavirThe metabolism of Risperidone can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Risperidone.Approved
ScopolamineThe serum concentration of Risperidone can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Risperidone.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Risperidone.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Risperidone is combined with Uc1010.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Risperidone is combined with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Risperidone can be decreased when combined with Sertraline.Approved
SevofluraneSevoflurane may increase the hypotensive activities of Risperidone.Approved, Vet Approved
SildenafilThe metabolism of Risperidone can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Risperidone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Risperidone can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Risperidone can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Risperidone can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Risperidone.Approved, Investigational
Sodium NitriteSodium Nitrite may increase the hypotensive activities of Risperidone.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved
SorafenibThe serum concentration of Risperidone can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolSotalol may increase the hypotensive activities of Risperidone.Approved
SpironolactoneSpironolactone may increase the hypotensive activities of Risperidone.Approved
St. John's WortThe serum concentration of Risperidone can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Risperidone can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Risperidone can be increased when it is combined with Stiripentol.Approved
StreptokinaseStreptokinase may increase the hypotensive activities of Risperidone.Approved
StreptozocinThe serum concentration of Risperidone can be decreased when it is combined with Streptozocin.Approved
SufentanilSufentanil may increase the hypotensive activities of Risperidone.Approved, Investigational
SulfinpyrazoneThe serum concentration of Risperidone can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleRisperidone may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Risperidone.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Risperidone is combined with Sulpiride.Approved
SumatriptanThe serum concentration of Risperidone can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Risperidone can be increased when it is combined with Sunitinib.Approved, Investigational
SuvorexantRisperidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrineThe serum concentration of Risperidone can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Risperidone can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Risperidone can be decreased when it is combined with Tamoxifen.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Risperidone.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Risperidone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Risperidone is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Risperidone can be increased when it is combined with Taurocholic Acid.Experimental
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Risperidone.Approved
TelaprevirThe metabolism of Risperidone can be decreased when combined with Telaprevir.Withdrawn
TelavancinRisperidone may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Risperidone can be decreased when combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Risperidone.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Risperidone.Approved
TemsirolimusThe serum concentration of Risperidone can be increased when it is combined with Temsirolimus.Approved
TerazosinTerazosin may increase the hypotensive activities of Risperidone.Approved
TerbinafineThe metabolism of Risperidone can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Risperidone can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Risperidone can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Risperidone can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Risperidone.Approved
TetracaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Risperidone is combined with Tetrodotoxin.Investigational
ThalidomideRisperidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Risperidone is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Risperidone.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Risperidone.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Risperidone is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Risperidone is combined with Tiagabine.Approved
TianeptineTianeptine may decrease the antihypertensive activities of Risperidone.Approved
TiaprideThe risk or severity of adverse effects can be increased when Risperidone is combined with Tiapride.Approved, Investigational
TicagrelorThe serum concentration of Risperidone can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Risperidone can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Risperidone is combined with Tiletamine.Vet Approved
TimololTimolol may increase the hypotensive activities of Risperidone.Approved
TipranavirThe metabolism of Risperidone can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Risperidone.Approved
TocilizumabThe serum concentration of Risperidone can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Risperidone.Approved
TolazolineTolazoline may increase the hypotensive activities of Risperidone.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Risperidone.Approved
TolcaponeTolcapone may increase the hypotensive activities of Risperidone.Approved, Withdrawn
TolvaptanThe serum concentration of Risperidone can be increased when it is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Risperidone is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Risperidone.Approved
ToremifeneRisperidone may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Risperidone.Approved, Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Risperidone.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Risperidone is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Risperidone.Approved
TrazodoneThe serum concentration of Risperidone can be decreased when it is combined with Trazodone.Approved, Investigational
TretinoinTretinoin may increase the hypotensive activities of Risperidone.Approved, Investigational, Nutraceutical
TriamtereneTriamterene may increase the hypotensive activities of Risperidone.Approved
TriazolamThe risk or severity of adverse effects can be increased when Risperidone is combined with Triazolam.Approved
TrifluoperazineThe serum concentration of Risperidone can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Risperidone can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Risperidone can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may decrease the antihypertensive activities of Risperidone.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Risperidone is combined with Triprolidine.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Risperidone.Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Risperidone.Approved, Investigational
ValsartanValsartan may increase the hypotensive activities of Risperidone.Approved, Investigational
VandetanibRisperidone may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibRisperidone may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineThe metabolism of Risperidone can be decreased when combined with Venlafaxine.Approved
VerapamilThe serum concentration of Risperidone can be increased when it is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Risperidone is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Risperidone.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Risperidone.Approved, Investigational
VinblastineThe serum concentration of Risperidone can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Risperidone can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Risperidone can be increased when it is combined with Vinorelbine.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Risperidone.Approved, Investigational
VoriconazoleThe metabolism of Risperidone can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Risperidone is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Risperidone is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Risperidone is combined with Ziconotide.Approved
ZimelidineThe metabolism of Risperidone can be decreased when combined with Zimelidine.Withdrawn
ZiprasidoneRisperidone may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Risperidone.Approved, Investigational
ZolpidemRisperidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Risperidone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Risperidone is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Risperidone is combined with Zotepine.Approved
ZuclopenthixolRisperidone may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceUS4804663
General References
  1. Altschuler EL, Kast RE: The atypical antipsychotic agents ziprasidone [correction of zisprasidone], risperdone and olanzapine as treatment for and prophylaxis against progressive multifocal leukoencephalopathy. Med Hypotheses. 2005;65(3):585-6. [PubMed:16004936 ]
  2. Bostwick JR, Guthrie SK, Ellingrod VL: Antipsychotic-induced hyperprolactinemia. Pharmacotherapy. 2009 Jan;29(1):64-73. doi: 10.1592/phco.29.1.64. [PubMed:19113797 ]
  3. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153 ]
  4. Kemp DE, Canan F, Goldstein BI, McIntyre RS: Long-acting risperidone: a review of its role in the treatment of bipolar disorder. Adv Ther. 2009 Jun;26(6):588-99. doi: 10.1007/s12325-009-0039-0. Epub 2009 Jun 26. [PubMed:19562274 ]
  5. Szarfman A, Tonning JM, Levine JG, Doraiswamy PM: Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy. 2006 Jun;26(6):748-58. [PubMed:16716128 ]
  6. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577 ]
  7. Yamanouchi Y, Iwata N, Suzuki T, Kitajima T, Ikeda M, Ozaki N: Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J. 2003;3(6):356-61. [PubMed:14610521 ]
External Links
ATC CodesN05AX08 — Risperidone
AHFS Codes
  • 28:16.08.04
PDB EntriesNot Available
FDA labelDownload (2.54 MB)
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers5
1CompletedBasic ScienceBipolar Disorder (BD) / Depressive Disorders / Psychotic Disorder NOS / Schizophrenic Disorders1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentBipolar Disorder (BD)1
1CompletedTreatmentChild Development Disorders, Pervasive1
1CompletedTreatmentDyskinesia, Drug-Induced1
1CompletedTreatmentFasting1
1CompletedTreatmentFed1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
1CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders4
1CompletedTreatmentSchizophrenic Disorders6
1RecruitingNot AvailableAntipsychotics / Immunoassay1
1RecruitingTreatmentSchizophrenic Disorders1
1TerminatedDiagnosticSchizophrenic Disorders1
1Unknown StatusNot AvailableHealthy Volunteers / Pharmacogenetics1
1Unknown StatusTreatmentCocaine-Related Disorders1
1, 2CompletedBasic ScienceSchizotypal Personality Disorder1
1, 2CompletedTreatmentChild Development Disorders, Pervasive1
1, 2CompletedTreatmentPost-Traumatic Stress Disorder (PTSD)1
1, 2CompletedTreatmentSubjects Had Unipolar, Non-psychotic Major Depression1
1, 2RecruitingBasic ScienceSchizophrenic Disorders1
1, 2WithdrawnTreatmentSchizophrenic Disorders1
2CompletedPreventionHealthy Volunteers1
2CompletedTreatmentAlcoholism / Dual Diagnosis / Schizophrenic Disorders1
2CompletedTreatmentAttention Deficit Disorder With Hyperactivity1
2CompletedTreatmentAutism, Early Infantile1
2CompletedTreatmentChronic Schizophrenia / Schizoaffective Disorders1
2CompletedTreatmentCocaine-Related Disorders3
2CompletedTreatmentCocaine-Related Disorders / Substance-Related Disorders2
2CompletedTreatmentDementias1
2CompletedTreatmentDependence, Cocaine1
2CompletedTreatmentEfficacy / Iloperidone / Schizophrenic Disorders1
2CompletedTreatmentGilles de la Tourette's Syndrome1
2CompletedTreatmentPost-Traumatic / Stress Disorders1
2CompletedTreatmentSchizophrenic Disorders12
2RecruitingTreatmentMenopausal Hot Flushes / Premenstrual Syndrome1
2RecruitingTreatmentSchizophrenia, Acute Episode1
2RecruitingTreatmentTreatment-resistant Schizophrenia1
2TerminatedTreatmentCocaine-Related Disorders2
2TerminatedTreatmentMajor Depressive Disorder With Panic Attacks / Panic Disorders1
2TerminatedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
2Unknown StatusTreatmentSchizophrenic Disorders1
2WithdrawnTreatmentSchizophrenic Disorders1
2, 3CompletedTreatmentAutism, Early Infantile1
2, 3CompletedTreatmentPost-Traumatic Stress Disorder (PTSD)1
2, 3CompletedTreatmentSchizophrenic Disorders3
2, 3TerminatedTreatmentCognitive Effect on Schizophrenic Patients / Schizophrenic Disorders1
2, 3TerminatedTreatmentSchizophrenic Disorders1
2, 3WithdrawnTreatmentDiabetes1
3CompletedNot AvailableBipolar Disorder (BD)1
3CompletedDiagnosticAdjustment Disorder / Attention Deficit/Hyperactivity Disorder (ADHD) / Bipolar Disorder (BD) / Impulse Control Disorders / Intermittent Explosive Disorder / Oppositional Defiant Disorder / Pervasive Developmental Disorder NOS1
3CompletedPreventionBipolar Disorder (BD)1
3CompletedPreventionSchizophrenic Disorders1
3CompletedTreatmentAlzheimer's Disease (AD) / Dementia, Vascular / Dementias3
3CompletedTreatmentAlzheimer's Disease (AD) / Dementias / Psychiatric Disorder NOS1
3CompletedTreatmentAnxiety Disorder1
3CompletedTreatmentAnxiety Disorder / Bipolar Disorder (BD)1
3CompletedTreatmentAsperger's Syndrome / Autistic Disorder / DCild Development Disorders, Pervasive / Developmental Disability / Rett's Syndrome1
3CompletedTreatmentAttention Deficit and Disruptive Behavior Disorders1
3CompletedTreatmentAutistic Disorder1
3CompletedTreatmentAutistic Disorder in Children and Adolescents1
3CompletedTreatmentBipolar Disorder (BD)6
3CompletedTreatmentBipolar Disorder (BD) / Manic Disorder3
3CompletedTreatmentAcute Manic episode / Bipolar Disorder (BD)2
3CompletedTreatmentBipolar I Disorder1
3CompletedTreatmentCessation, Smoking / Schizophrenic Disorders1
3CompletedTreatmentChild Behavior Disorders / Learning Disorders1
3CompletedTreatmentDepressive Disorders / Depressive State / Major Depressive Disorder (MDD)1
3CompletedTreatmentDepressive State1
3CompletedTreatmentDepressive State / Schizophrenic Disorders1
3CompletedTreatmentDevelopmental Delay Disorders / Mental Retardation1
3CompletedTreatmentMajor Depressive Disorder (MDD)1
3CompletedTreatmentMental Health / Psychiatric Disorder NOS / Psychotic Disorder NOS / Schizophrenic Disorders1
3CompletedTreatmentOppositional Defiant Disorder3
3CompletedTreatmentPsychotic Disorder NOS / Schizophrenic Disorders8
3CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders5
3CompletedTreatmentSchizophrenia and Schizoaffective Disorder1
3CompletedTreatmentSchizophrenic Disorders18
3RecruitingTreatmentAnxiety Disorder / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
3RecruitingTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
3RecruitingTreatmentSchizophrenic Disorders2
3TerminatedTreatmentAlzheimer's Disease (AD) / Dementias1
3TerminatedTreatmentBipolar I Disorder / Metabolic Syndromes / Schizoaffective Disorders / Schizophrenic Disorders1
3TerminatedTreatmentMajor Depression With Psychotic Features1
3TerminatedTreatmentSchizophrenic Disorders3
3Unknown StatusNot AvailableSchizoaffective Disorders1
3Unknown StatusTreatmentMajor Depressive Disorder (MDD)1
3Unknown StatusTreatmentPsychosis Nos/Other1
3Unknown StatusTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
3WithdrawnTreatmentSchizophrenic Disorders1
4Active Not RecruitingTreatmentCannabis Abuse / Cannabis Dependence / Dual Diagnosis / Schizophrenic Disorders1
4Active Not RecruitingTreatmentSchizoaffective Disorders / Schizophrenia and Disorders With Psychotic Features / Schizophrenic Disorders1
4CompletedNot AvailableAntipsychotic Agents / Physiological Effects of Drugs / Psychiatric Disorder NOS / Psychotropic Drugs / Schizophrenic Disorders / Therapeutic Uses / Tranquilizing Agents1
4CompletedNot AvailableSchizoaffective Disorders / Schizophrenic Disorders1
4CompletedNot AvailableSchizophrenic Disorders2
4CompletedBasic ScienceHealthy Volunteers / Schizophrenic Disorders1
4CompletedPreventionPost-Traumatic Stress Disorder (PTSD)1
4CompletedPreventionSchizophrenic Disorders2
4CompletedSupportive CareAutistic Disorder1
4CompletedTreatmentAcute Agitation1
4CompletedTreatmentAcute Agitation / Aggressive Behavior / Alzheimer's Disease (AD) / Psychotic Disorder NOS1
4CompletedTreatmentAcute Agitation / Alzheimer's Disease (AD) / Psychosis1
4CompletedTreatmentAdhd / Aggressive Behavior / Bipolar Disorder (BD) / Oppositional Defiant Disorder / PDD1
4CompletedTreatmentAggressive Behavior1
4CompletedTreatmentAlcohol Abuse / Psychotic Disorder NOS / Schizophrenic Disorders / Substance Abuse1
4CompletedTreatmentAlzheimer's Disease (AD) / Dementia, Alzheimer Type / Dementias / Senile Dementia, Alzheimer Type1
4CompletedTreatmentAlzheimer's Disease (AD) / Dementias / Schizophrenic Disorders1
4CompletedTreatmentAnorexia Nervosa (AN)1
4CompletedTreatmentAnxiety Disorder / Moods Disorders / Schizophrenic Disorders1
4CompletedTreatmentAsperger's Disorder1
4CompletedTreatmentAutism, Early Infantile / Autistic Disorder1
4CompletedTreatmentAutistic Disorder / Bipolar Disorder (BD) / Conduct and Other Disruptive Behavior Disorders / Schizophrenic Disorders1
4CompletedTreatmentBipolar Disorder (BD)6
4CompletedTreatmentBipolar Disorder (BD) / Generalized Anxiety Disorder (GAD) / Panic Disorders1
4CompletedTreatmentBipolar Disorder (BD) / Mania1
4CompletedTreatmentBipolar Spectrum Disorder1
4CompletedTreatmentBorderline Personality Disorder (BPD)1
4CompletedTreatmentDementias2
4CompletedTreatmentDepression, Bipolar / Substance Abuse1
4CompletedTreatmentDiabetes Mellitus (DM) / Schizophrenic Disorders1
4CompletedTreatmentDiabetes / Hyperglycemias / Metabolic Syndromes / Schizophrenic Disorders1
4CompletedTreatmentEmergency Treatment / Psychotic Disorder NOS / Schizophrenic Disorders1
4CompletedTreatmentExtrapyramidal Syndrome / Schizophrenic Disorders1
4CompletedTreatmentHyperglycemias / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1
4CompletedTreatmentMethamphetamine Dependence1
4CompletedTreatmentNegative Symptoms / Schizophrenic Disorders1
4CompletedTreatmentNeuroleptic-Induced Tardive Dyskinesia1
4CompletedTreatmentPsychosis, Schizophrenia1
4CompletedTreatmentPsychosis / Schizophrenic Disorders1
4CompletedTreatmentPsychotic Disorder NOS2
4CompletedTreatmentPsychotic Disorder NOS / Schizophrenic Disorders2
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders8
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder2
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Substance Abuse / Substance Dependence1
4CompletedTreatmentSchizophrenia, Schizoaffective Disorder1
4CompletedTreatmentSchizophrenic Disorders27
4CompletedTreatmentSchizophrenic Disorders / Type 2 Diabetes Mellitus1
4Enrolling by InvitationTreatmentPsychosis / Psychotic Disorder NOS / Schizophrenic Disorders1
4Enrolling by InvitationTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
4Not Yet RecruitingTreatmentDiagnosis and Treatment of Depression1
4Not Yet RecruitingTreatmentSchizophrenic Disorders1
4RecruitingDiagnosticFragile X Syndrome (FXS) / Velocardiofacial Syndrome / Williams Syndrome1
4RecruitingTreatmentBipolar Disorder (BD)1
4RecruitingTreatmentSchizophrenia (Recent-onset)1
4RecruitingTreatmentSchizophrenic Disorders2
4TerminatedNot AvailableHigh Risk MC4R Genotype / Low Risk MC4R Genotype / One Week or Less Antipsychotic Lifetime Exposure1
4TerminatedNot AvailableSchizophrenic Disorders1
4TerminatedBasic ScienceSchizophrenic Disorders1
4TerminatedPreventionSchizophrenic Disorders1
4TerminatedTreatmentAcute Agitation / Delirium1
4TerminatedTreatmentMajor Depressive Disorder (MDD)1
4TerminatedTreatmentMethamphetamine Dependence1
4TerminatedTreatmentSchizophrenic Disorders7
4Unknown StatusDiagnosticSchizophrenic Disorders1
4Unknown StatusTreatmentAttention Deficit Disorder With Hyperactivity1
4Unknown StatusTreatmentAttention Deficit/Hyperactivity Disorder / Oppositional Defiant Disorder1
4Unknown StatusTreatmentDelirium1
4Unknown StatusTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
4Unknown StatusTreatmentSchizophrenia, First-Episode1
4Unknown StatusTreatmentSchizophrenic Disorders4
4WithdrawnPreventionSchizophrenic Disorders1
4WithdrawnTreatmentTreatment Resistant Depression (TRD)1
Not AvailableActive Not RecruitingTreatmentSchizophrenia Relapse1
Not AvailableCompletedNot AvailableBipolar Disorder (BD)1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Metabolic Syndromes / Psychotic Disorder NOS1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableNormal Volunteers1
Not AvailableCompletedNot AvailablePatients Already Taking Risperidone for Clinical Indications1
Not AvailableCompletedBasic ScienceImaging of the Brain and Antipsychotics / Neuronal Network Changes1
Not AvailableCompletedBasic ScienceSchizophrenic Disorders1
Not AvailableCompletedDiagnosticProdromal Schizophrenia / Psychotic Disorder NOS1
Not AvailableCompletedDiagnosticSchizophrenic Disorders1
Not AvailableCompletedHealth Services ResearchPsychomotor Agitation / Sleep Disorders, Circadian Rhythm / Sleeplessness1
Not AvailableCompletedScreeningBMI >30 kg/m2 / Diabetes / Metabolic Syndromes1
Not AvailableCompletedTreatmentAlzheimer's Disease (AD)1
Not AvailableCompletedTreatmentAlzheimer's Disease (AD) / Dementias1
Not AvailableCompletedTreatmentAutistic Disorder1
Not AvailableCompletedTreatmentBipolar Disorder (BD)1
Not AvailableCompletedTreatmentBipolar Disorder (BD) / Bipolar I / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
Not AvailableCompletedTreatmentBipolar Disorder (BD) / Dependence, Cocaine / Methamphetamine Dependence1
Not AvailableCompletedTreatmentCannabis-Related Disorder / Psychotic Disorder NOS / Schizophrenic Disorders / Substance-Related Disorders1
Not AvailableCompletedTreatmentChild Development Disorders, Pervasive1
Not AvailableCompletedTreatmentDelusional Disorder / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
Not AvailableCompletedTreatmentMajor Depression With Panic Attacks / Panic Disorders1
Not AvailableCompletedTreatmentObsessive-Compulsive Disorder (OCD)1
Not AvailableCompletedTreatmentPsychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorders1
Not AvailableCompletedTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
Not AvailableCompletedTreatmentSchizophrenic Disorders3
Not AvailableCompletedTreatmentSchizophrenic Disorders / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentSchizotypal Personality Disorder1
Not AvailableNot Yet RecruitingNot AvailableBipolar Disorder (BD)1
Not AvailableNot Yet RecruitingTreatmentSchizophrenic Disorders1
Not AvailableRecruitingNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / Hospital-acquired bacterial pneumonia / Hypercholesterolaemia / Hyperlipidemias / Hypertensive / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal1
Not AvailableRecruitingNot AvailableBipolar Disorder (BD)1
Not AvailableRecruitingNot AvailableBipolar Disorder (BD) / First-Episode Psychosis1
Not AvailableRecruitingNot AvailableMicrognathia / Schizophrenic Disorders1
Not AvailableRecruitingNot AvailablePsychosis / Schizoaffective Disorders / Schizophrenic Disorders1
Not AvailableRecruitingNot AvailablePsychotic Disorder NOS1
Not AvailableRecruitingNot AvailableSchizophrenic Disorders2
Not AvailableRecruitingTreatmentPsychosis Not Otherwise Specified (NOS) / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform1
Not AvailableRecruitingTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
Not AvailableSuspendedTreatmentPsychotic Disorder Not Otherwise Specified / Schizoaffective Disorders / Schizophrenic Disorders / Severe Bipolar Disorder With Psychotic Features1
Not AvailableTerminatedNot AvailableSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
Not AvailableTerminatedNot AvailableSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorders1
Not AvailableTerminatedBasic ScienceSchizophrenic Disorders1
Not AvailableTerminatedTreatmentAggressive Behavior / Psychosis1
Not AvailableUnknown StatusNot AvailableSchizophrenic Disorders1
Not AvailableUnknown StatusPreventionPsychotic Disorder NOS1
Not AvailableUnknown StatusTreatmentBorderlone Personality Disorder1
Not AvailableUnknown StatusTreatmentCannabis Dependence / Psychostimulant Dependence1
Not AvailableUnknown StatusTreatmentSchizophrenic Disorders2
Not AvailableUnknown StatusTreatmentSevere Mood Dysregulation1
Not AvailableUnknown StatusTreatmentTreatment Resistant Depression (TRD)1
Not AvailableWithdrawnTreatmentActive Suicidal Ideations / Depressive State / Impulsivity1
Pharmacoeconomics
Manufacturers
  • Ortho mcneil janssen pharmaceuticals inc
  • Ortho mcneil janssen pharmaceutical inc
  • Apotex inc richmond hill
  • Aurobindo pharma ltd
  • Dr reddys laboratories ltd
  • Precision dose inc
  • Roxane laboratories inc
  • Teva pharmaceuticals usa inc
  • Wockhardt ltd
  • Par pharmaceutical inc
  • Ranbaxy laboratories inc
  • Sandoz inc
  • Zydus pharmaceuticals usa inc
  • Actavis totowa llc
  • Apotex inc
  • Cadista pharmaceuticals inc
  • Mylan pharmaceuticals inc
  • Pliva hrvatska doo
  • Ratiopharm
  • Synthon pharmaceuticals inc
  • Torrent pharmaceuticals ltd
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
  • West ward pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
TabletOral0.50 mg
TabletOral1.0 mg
TabletOral2.0 mg
TabletOral3.0 mg
TabletOral4.0 mg
Tablet, orally disintegratingOral0.5 mg
Tablet, orally disintegratingOral1 mg
Tablet, orally disintegratingOral2 mg
Tablet, orally disintegratingOral3 mg
Tablet, orally disintegratingOral4 mg
TabletOral0.25 mg
TabletOral0.5 mg
TabletOral1 mg
TabletOral2 mg
TabletOral3 mg
TabletOral4 mg
TabletOral5 mg
Injection, powder, for suspension, extended release; kitIntramuscular12.5 mg
Injection, powder, for suspension, extended release; kitIntramuscular25 mg
Injection, powder, for suspension, extended release; kitIntramuscular37.5 mg
Injection, powder, for suspension, extended release; kitIntramuscular50 mg
Kit
SolutionOral1 mg
SolutionOral1 mg/mL
TabletOral.25 mg/1
TabletOral.5 mg/1
TabletOral1 mg/1
TabletOral2 mg/1
TabletOral3 mg/1
TabletOral4 mg/1
Tablet, coatedOral.25 mg/1
Tablet, coatedOral.5 mg/1
Tablet, coatedOral1 mg/1
Tablet, coatedOral2 mg/1
Tablet, coatedOral3 mg/1
Tablet, coatedOral4 mg/1
Tablet, film coatedOral.25 mg/1
Tablet, film coatedOral.5 mg/1
Tablet, film coatedOral1 mg/1
Tablet, film coatedOral2 mg/1
Tablet, film coatedOral3 mg/1
Tablet, film coatedOral4 mg/1
Tablet, orally disintegratingOral.25 mg/1
Tablet, orally disintegratingOral.5 mg/1
Tablet, orally disintegratingOral1 mg/1
Tablet, orally disintegratingOral2 mg/1
Tablet, orally disintegratingOral3 mg/1
Tablet, orally disintegratingOral4 mg/1
Prices
Unit descriptionCostUnit
Risperdal consta 50 mg syr592.93USD syringe
Risperdal consta 37.5 mg syr444.68USD syringe
Risperdal consta 25 mg syr296.46USD syringe
Risperdal 1 mg/ml Solution 30ml Bottle204.42USD bottle
Risperdal M-TAB 28 1 mg Dispersible Tablet Box196.08USD box
Risperdal M-TAB 28 0.5 mg Dispersible Tablet Bottle167.82USD bottle
Risperidone 1 mg/ml Solution 30ml Bottle158.66USD bottle
Risperdal consta 12.5 mg syr148.22USD syringe
Risperdal m-tab 4 mg odt18.55USD tablet
Risperdal 4 mg tablet16.47USD tablet
Risperidone m-tab 4 mg odt15.16USD tablet
Risperdal m-tab 3 mg odt13.81USD tablet
Risperdal 3 mg tablet11.45USD tablet
Risperidone m-tab 3 mg odt11.29USD tablet
Risperdal m-tab 2 mg odt10.95USD tablet
Risperidone 4 mg tablet9.0USD tablet
Risperidone m-tab 2 mg odt8.95USD tablet
Risperdal 2 mg tablet6.94USD tablet
Risperdal m-tab 1 mg odt6.73USD tablet
Risperidone 3 mg tablet6.63USD tablet
Risperdal 1 mg tablet6.12USD tablet
Risperdal m-tab 0.5 mg odt5.76USD tablet
Risperidone 2 mg tablet5.59USD tablet
Risperidone m-tab 1 mg odt5.5USD tablet
Risperidone M-TAB 0.5 mg Dispersible Tablet4.9USD dispersible tablet
Risperidone m-tab 0.5 mg odt4.71USD tablet
Risperdal M-Tab 4 mg Disintegrating Tablet4.6USD tablet
Risperdal 0.25 mg tablet4.56USD tablet
Risperidone 0.25 mg odt4.48USD tablet
Risperdal 0.5 mg tablet3.62USD tablet
Risperdal M-Tab 3 mg Disintegrating Tablet3.44USD tablet
Risperidone 1 mg tablet3.27USD tablet
Risperidone 0.5 mg tablet3.03USD tablet
Apo-Risperidone 4 mg Tablet2.53USD tablet
Co Risperidone 4 mg Tablet2.53USD tablet
Mylan-Risperidone 4 mg Tablet2.53USD tablet
Novo-Risperidone 4 mg Tablet2.53USD tablet
Phl-Risperidone 4 mg Tablet2.53USD tablet
Pms-Risperidone 4 mg Tablet2.53USD tablet
Ran-Risperidone 4 mg Tablet2.53USD tablet
Ratio-Risperidone 4 mg Tablet2.53USD tablet
Rbx-Risperidone 4 mg Tablet2.53USD tablet
Sandoz Risperidone 4 mg Tablet2.53USD tablet
Risperdal M-Tab 2 mg Disintegrating Tablet2.29USD tablet
Apo-Risperidone 3 mg Tablet1.9USD tablet
Co Risperidone 3 mg Tablet1.9USD tablet
Mylan-Risperidone 3 mg Tablet1.9USD tablet
Novo-Risperidone 3 mg Tablet1.9USD tablet
Phl-Risperidone 3 mg Tablet1.9USD tablet
Pms-Risperidone 3 mg Tablet1.9USD tablet
Ran-Risperidone 3 mg Tablet1.9USD tablet
Ratio-Risperidone 3 mg Tablet1.9USD tablet
Rbx-Risperidone 3 mg Tablet1.9USD tablet
Sandoz Risperidone 3 mg Tablet1.9USD tablet
Risperidone 0.25 mg tablet1.88USD tablet
Apo-Risperidone 2 mg Tablet1.26USD tablet
Co Risperidone 2 mg Tablet1.26USD tablet
Mylan-Risperidone 2 mg Tablet1.26USD tablet
Novo-Risperidone 2 mg Tablet1.26USD tablet
Phl-Risperidone 2 mg Tablet1.26USD tablet
Pms-Risperidone 2 mg Tablet1.26USD tablet
Ran-Risperidone 2 mg Tablet1.26USD tablet
Ratio-Risperidone 2 mg Tablet1.26USD tablet
Rbx-Risperidone 2 mg Tablet1.26USD tablet
Sandoz Risperidone 2 mg Tablet1.26USD tablet
Risperdal M-Tab 1 mg Disintegrating Tablet1.16USD tablet
Risperdal M-Tab 0.5 mg Disintegrating Tablet0.84USD tablet
Apo-Risperidone 1 mg Tablet0.63USD tablet
Co Risperidone 1 mg Tablet0.63USD tablet
Mylan-Risperidone 1 mg Tablet0.63USD tablet
Novo-Risperidone 1 mg Tablet0.63USD tablet
Phl-Risperidone 1 mg Tablet0.63USD tablet
Pms-Risperidone 1 mg Tablet0.63USD tablet
Ran-Risperidone 1 mg Tablet0.63USD tablet
Ratio-Risperidone 1 mg Tablet0.63USD tablet
Rbx-Risperidone 1 mg Tablet0.63USD tablet
Sandoz Risperidone 1 mg Tablet0.63USD tablet
Apo-Risperidone 0.5 mg Tablet0.46USD tablet
Co Risperidone 0.5 mg Tablet0.46USD tablet
Mylan-Risperidone 0.5 mg Tablet0.46USD tablet
Novo-Risperidone 0.5 mg Tablet0.46USD tablet
Phl-Risperidone 0.5 mg Tablet0.46USD tablet
Pms-Risperidone 0.5 mg Tablet0.46USD tablet
Ran-Risperidone 0.5 mg Tablet0.46USD tablet
Ratio-Risperidone 0.5 mg Tablet0.46USD tablet
Rbx-Risperidone 0.5 mg Tablet0.46USD tablet
Sandoz Risperidone 0.5 mg Tablet0.46USD tablet
Apo-Risperidone 0.25 mg Tablet0.27USD tablet
Co Risperidone 0.25 mg Tablet0.27USD tablet
Mylan-Risperidone 0.25 mg Tablet0.27USD tablet
Novo-Risperidone 0.25 mg Tablet0.27USD tablet
Phl-Risperidone 0.25 mg Tablet0.27USD tablet
Pms-Risperidone 0.25 mg Tablet0.27USD tablet
Ran-Risperidone 0.25 mg Tablet0.27USD tablet
Ratio-Risperidone 0.25 mg Tablet0.27USD tablet
Rbx-Risperidone 0.25 mg Tablet0.27USD tablet
Sandoz Risperidone 0.25 mg Tablet0.27USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6110921 No1993-11-192013-11-19Us
CA2406536 No2009-12-222021-04-19Canada
CA2194564 No1998-01-272015-07-04Canada
US6667061 Yes2000-11-252020-11-25Us
US5792477 Yes1997-11-022017-11-02Us
US5916598 Yes1997-11-022017-11-02Us
US6379703 Yes1999-06-302019-06-30Us
US6403114 Yes1997-11-022017-11-02Us
US6596316 Yes1999-06-302019-06-30Us
US6194006 Yes1999-06-302019-06-30Us
US6224905 Yes1997-12-102017-12-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)170 °CPhysProp
water solubility2.8mg/LNot Available
logP2.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.171 mg/mLALOGPS
logP3.27ALOGPS
logP2.63ChemAxon
logS-3.4ALOGPS
pKa (Strongest Basic)8.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area61.94 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity114.55 m3·mol-1ChemAxon
Polarizability45.27 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9925
Caco-2 permeable-0.5057
P-glycoprotein substrateSubstrate0.6163
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.9361
Renal organic cation transporterInhibitor0.6491
CYP450 2C9 substrateNon-substrate0.8235
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.82
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8459
Ames testNon AMES toxic0.5302
CarcinogenicityNon-carcinogens0.8204
BiodegradationNot ready biodegradable0.99
Rat acute toxicity3.8290 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.65
hERG inhibition (predictor II)Inhibitor0.8062
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF , positivesplash10-03di-0000900000-b0fe7f692a00657a0970View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF , positivesplash10-03dl-0800900000-4e0f5ed855c5bb92c98fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF , positivesplash10-01ox-0900600000-8473cdb789508bd753a4View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF , positivesplash10-0006-0900000000-3d06f3ad1210b9482139View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF , positivesplash10-0006-0900000000-d0dcf9d7f61a2c2bc652View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-03di-0000900000-dde599ea867efca2809bView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-0006-0900300000-9a423e6e6775ee918924View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-0006-0900000000-b3a1059a8514321aac84View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-0006-0900000000-3160d58bf1d154a8d21cView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-0006-2900000000-530259828e362c7f2a3cView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-02u3-8900000000-c5ae8612478a7ea315c0View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-066r-9200000000-466435c830554a2d51eaView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-066r-9100000000-352e00f2fbc78e81df2cView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-066r-9000000000-de0b42c9894812c69015View in MoNA
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-03dl-1901800000-c9a45676bc3a1d1829b7View in MoNA
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-0a4i-2980000000-3574e0025348c64db6fcView in MoNA
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-03dl-0900800000-6edaf8e46040d5648f3fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-0a4i-0790000000-e0be2a4dba2d14313d6cView in MoNA
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-0006-2900000000-81e94f588db0cd3c9ea8View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pyridopyrimidines. These are compounds containing a pyridopyrimidine, which consists of a pyridine fused to a pyrimidine. Pyridine is 6-membered ring consisting of five carbon atoms and a nitrogen atom. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridopyrimidines
Sub ClassNot Available
Direct ParentPyridopyrimidines
Alternative ParentsBenzisoxazoles / Pyrimidones / Aralkylamines / Pyridines and derivatives / Piperidines / Aryl fluorides / Benzenoids / Heteroaromatic compounds / Isoxazoles / Trialkylamines
SubstituentsPyridopyrimidine / Benzisoxazole / Aralkylamine / Pyrimidone / Aryl fluoride / Aryl halide / Piperidine / Pyridine / Benzenoid / Pyrimidine
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptorsorganofluorine compound, pyridopyrimidine, 1,2-benzoxazoles, heteroarylpiperidine (CHEBI:8871 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Uniprot Name:
5-hydroxytryptamine receptor 2A
Molecular Weight:
52602.58 Da
References
  1. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153 ]
  2. Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52. [PubMed:15992090 ]
  3. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  4. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Uniprot Name:
D(2) dopamine receptor
Molecular Weight:
50618.91 Da
References
  1. Catafau AM, Corripio I, Perez V, Martin JC, Schotte A, Carrio I, Alvarez E: Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response. Psychiatry Res. 2006 Dec 1;148(2-3):175-83. Epub 2006 Oct 23. [PubMed:17059881 ]
  2. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153 ]
  3. Lane HY, Lee CC, Chang YC, Lu CT, Huang CH, Chang WH: Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. Int J Neuropsychopharmacol. 2004 Dec;7(4):461-70. Epub 2004 May 12. [PubMed:15140279 ]
  4. Naiker DV, Catts SV, Catts VS, Bedi KS, Bryan-Lluka LJ: Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. Eur J Pharmacol. 2006 Jul 1;540(1-3):87-90. Epub 2006 May 11. [PubMed:16730699 ]
  5. Remington G, Mamo D, Labelle A, Reiss J, Shammi C, Mannaert E, Mann S, Kapur S: A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry. 2006 Mar;163(3):396-401. [PubMed:16513859 ]
  6. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Uniprot Name:
D(3) dopamine receptor
Molecular Weight:
44224.335 Da
References
  1. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908 ]
  2. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Uniprot Name:
D(4) dopamine receptor
Molecular Weight:
48359.86 Da
References
  1. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908 ]
  2. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Uniprot Name:
Alpha-1A adrenergic receptor
Molecular Weight:
51486.005 Da
References
  1. Eltze M: In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1996 Jan 4;295(1):69-73. [PubMed:8925876 ]
  2. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153 ]
  3. Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52. [PubMed:15992090 ]
  4. Nourian Z, Mow T, Muftic D, Burek S, Pedersen ML, Matz J, Mulvany MJ: Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function. Psychopharmacology (Berl). 2008 Jul;199(1):15-27. doi: 10.1007/s00213-007-1064-9. Epub 2008 Jun 10. [PubMed:18542932 ]
  5. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  6. Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10. [PubMed:7691623 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Uniprot Name:
Alpha-1B adrenergic receptor
Molecular Weight:
56835.375 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Eltze M: In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1996 Jan 4;295(1):69-73. [PubMed:8925876 ]
  3. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153 ]
  4. Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52. [PubMed:15992090 ]
  5. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  6. Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10. [PubMed:7691623 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Uniprot Name:
5-hydroxytryptamine receptor 1D
Molecular Weight:
41906.38 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Uniprot Name:
Histamine H1 receptor
Molecular Weight:
55783.61 Da
References
  1. Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52. [PubMed:15992090 ]
  2. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  3. Schreiber S, Backer MM, Weizman R, Pick CG: Augmentation of opioid induced antinociception by the atypical antipsychotic drug risperidone in mice. Neurosci Lett. 1997 May 30;228(1):25-8. [PubMed:9197279 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Uniprot Name:
Alpha-2A adrenergic receptor
Molecular Weight:
48956.275 Da
References
  1. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153 ]
  2. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistagonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Uniprot Name:
Alpha-2B adrenergic receptor
Molecular Weight:
49565.8 Da
References
  1. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153 ]
  2. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Uniprot Name:
Alpha-2C adrenergic receptor
Molecular Weight:
49521.585 Da
References
  1. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153 ]
  2. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Uniprot Name:
5-hydroxytryptamine receptor 2C
Molecular Weight:
51820.705 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Canton H, Verriele L, Millan MJ: Competitive antagonism of serotonin (5-HT)2C and 5-HT2A receptor-mediated phosphoinositide (PI) turnover by clozapine in the rat: a comparison to other antipsychotics. Neurosci Lett. 1994 Nov 7;181(1-2):65-8. [PubMed:7898773 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Uniprot Name:
5-hydroxytryptamine receptor 1A
Molecular Weight:
46106.335 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Uniprot Name:
D(1A) dopamine receptor
Molecular Weight:
49292.765 Da
References
  1. Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52. [PubMed:15992090 ]
  2. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Uniprot Name:
5-hydroxytryptamine receptor 7
Molecular Weight:
53554.43 Da
References
  1. Knight JA, Smith C, Toohey N, Klein MT, Teitler M: Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists. Mol Pharmacol. 2009 Feb;75(2):374-80. doi: 10.1124/mol.108.052084. Epub 2008 Nov 7. [PubMed:18996971 ]
  2. Toohey N, Klein MT, Knight J, Smith C, Teitler M: Human 5-HT7 receptor-induced inactivation of forskolin-stimulated adenylate cyclase by risperidone, 9-OH-risperidone and other "inactivating antagonists". Mol Pharmacol. 2009 Sep;76(3):552-9. doi: 10.1124/mol.109.056283. Epub 2009 Jun 9. [PubMed:19509219 ]
  3. Teitler M, Toohey N, Knight JA, Klein MT, Smith C: Clozapine and other competitive antagonists reactivate risperidone-inactivated h5-HT7 receptors: radioligand binding and functional evidence for GPCR homodimer protomer interactions. Psychopharmacology (Berl). 2010 Dec;212(4):687-97. doi: 10.1007/s00213-010-2001-x. Epub 2010 Sep 9. [PubMed:20827463 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Uniprot Name:
Cytochrome P450 2D6
Molecular Weight:
55768.94 Da
References
  1. Fang J, Bourin M, Baker GB: Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol. 1999 Feb;359(2):147-51. [PubMed:10048600 ]
  2. Hendset M, Molden E, Refsum H, Hermann M: Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. J Clin Psychopharmacol. 2009 Dec;29(6):537-41. doi: 10.1097/JCP.0b013e3181c17df0. [PubMed:19910717 ]
  3. Zhou SF: Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761-804. doi: 10.2165/11318070-000000000-00000. [PubMed:19902987 ]
  4. Zhou SF: Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000. [PubMed:19817501 ]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  6. Yasui-Furukori N, Hidestrand M, Spina E, Facciola G, Scordo MG, Tybring G: Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001 Oct;29(10):1263-8. [PubMed:11560868 ]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  8. Source [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Uniprot Name:
Cytochrome P450 3A4
Molecular Weight:
57342.67 Da
References
  1. Fang J, Bourin M, Baker GB: Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol. 1999 Feb;359(2):147-51. [PubMed:10048600 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Uniprot Name:
Cytochrome P450 3A5
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Uniprot Name:
Cytochrome P450 3A7
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Uniprot Name:
Multidrug resistance protein 1
Molecular Weight:
141477.255 Da
References
  1. Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. [PubMed:12031686 ]
  2. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186 ]
Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 10:31